

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2018298855 B2

- (54) Title
Long-acting formulations
- (51) International Patent Classification(s)
A61K 9/10 (2006.01) **A61P 31/06** (2006.01)
A61K 31/47 (2006.01) **A61P 31/08** (2006.01)
A61K 47/26 (2006.01)
- (21) Application No: **2018298855** (22) Date of Filing: **2018.07.13**
- (87) WIPO No: **WO19/012100**
- (30) Priority Data
- (31) Number (32) Date (33) Country
17181354.6 **2017.07.14** **EP**
18167463.1 **2018.04.16** **EP**
- (43) Publication Date: **2019.01.17**
(44) Accepted Journal Date: **2024.07.18**
- (71) Applicant(s)
Janssen Pharmaceutica NV
- (72) Inventor(s)
Andries, Koenraad Jozef Lodewijk Marcel;Bernini, Maristella;Basstanie, Esther Dina Guido
- (74) Agent / Attorney
Spruson & Ferguson, GPO Box 3898, Sydney, NSW, 2001, AU
- (56) Related Art
D JARY ET AL: "Bedaquiline loaded lipid nanoparticles: formulation, optimisation and in vitro assays", 1 May 2016 (2016-05-01), XP055418511, Retrieved from the Internet [retrieved on 20171024]
ERICA LESSEM ET AL: "An Activist's Guide to BEDAQUILINE (Sirturo)", 1 February 2013 (2013-02-01), pages 1 - 8, XP055251839, Retrieved from the Internet [retrieved on 20160219]
JAGDEEP SINGH ET AL: DRUG DELIVERY., vol. 23, no. 5, 12 June 2016 (2016-06-12), US, pages 1676 - 1698, XP055418518, ISSN: 1071-7544, DOI: 10.3109/10717544.2015.1074765
MOHAMMAD NASIRUDDIN ET AL: "Nanotechnology-Based Approach in Tuberculosis Treatment", TUBERCULOSIS RESEARCH AND TREATMENT, vol. 2017, 1 January 2017 (2017-01-01), pages 1 - 12, XP055418525, ISSN: 2090-150X, DOI: 10.1155/2017/4920209

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau



(10) International Publication Number

WO 2019/012100 A1

(43) International Publication Date

17 January 2019 (17.01.2019)

(51) International Patent Classification:

A61K 9/10 (2006.01) *A61P 31/06* (2006.01)
A61K 31/47 (2006.01) *A61P 31/08* (2006.01)
A61K 47/26 (2006.01)

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

(21) International Application Number:

PCT/EP2018/069066

Published:

— *with international search report (Art. 21(3))*

(22) International Filing Date:

13 July 2018 (13.07.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17181354.6 14 July 2017 (14.07.2017) EP
18167463.1 16 April 2018 (16.04.2018) EP

(71) Applicant: **JANSSEN PHARMACEUTICA NV**
[BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: **ANDRIES, Koenraad, Jozef, Lodewijk, Marcel**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **BERNINI, Maristella**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **BASTANIE, Esther, Dina, Guido**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).

(74) Agent: **PUREWAL, Savroop**; J&J Patent Law Department, Turnhoutseweg 30, 2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: LONG-ACTING FORMULATIONS

(57) Abstract: This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the anti- TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of a pathogenic mycobacterial infection.

Long-acting formulations

Field of the Invention

This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the ATP synthase inhibitor compound, bedaquiline (marketed as Sirturo®, where bedaquiline is in the form of its fumarate salt), suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment of bacterial infections, e.g. tuberculosis and the like.

Background of the Invention

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

Bedaquiline is a known anti-tuberculosis drug used in various combinations. It may be formulated in the form of a pharmaceutically acceptable salt, such as in the form of bedaquiline fumarate, marketed as Sirturo®. It is thought to act as an ATP synthase inhibitor, possessing a selectivity index of more than 20000 for mycobacterial ATP synthase versus eukaryotic mitochondrial ATP synthase.

Bedaquiline has already been reported as being useful in the treatment of mycobacterial infections, as well as being useful in killing dormant, latent, persistent mycobacteria, in particular *Mycobacterium tuberculosis*, and can consequently be used to treat latent TB. Such use of bedaquiline has been described in several publications including international patent documents WO 2004/011436 and WO 2006/067048. It is also known that bedaquiline is bactericidal against *Mycobacterium leprae*, for example as described in “Bacterial Activities of R207910 and other Antimicrobial Agents against *Mycobacterium leprae* in Mice”, Antimicrobial agents and Chemotherapy, April 2006, p 1558, and “The Diarylquinolone R207910 is Bactericidal against *Mycobacterium leprae* in mice and at Low Dose Administered Intermittently”, Antimicrobial agents and Chemotherapy, Sept 2009, p3989.

The goal of long-acting formulations can be to reduce drug burden. This is particularly useful for treatment regimens that may last several months.

The number and/or volume of dosage forms that need to be administered are commonly referred to as "pill burden". A high pill burden is undesirable for many reasons, such as

the frequency of intake, often combined with the inconvenience of having to swallow large dosage forms, as well as the need to store and transport a large number or volume of pills. A high pill burden increases the risk of patients not taking their entire dose, thereby failing to comply with the prescribed dosage regimen. As well as reducing the effectiveness of the treatment, this may also lead to the emergence of resistance (e.g. in the case of bedaquiline, bacterial resistance).

It would be attractive to provide therapy involving the administration of dosage forms at long time intervals such as one week or longer, or even one month or longer.

Various formulations are known in the art, including long-acting ones. For instance, micro- and nano-suspension technology is known for achieving long-acting formulations in the field of anti-HIV drugs, for instance as described in international patent applications WO 2007/147882 and WO 2012/140220. Further, nanoparticles known in the prior art have been described, for example, in EP-A-0 499 299. Such particles have an average particle size in the submicron range and consist of particles of a crystalline drug substance having a surface modifier adsorbed on their surface. Nanoparticles have also been used to formulate poorly water-soluble active ingredients.

Long-acting formulations of the anti-tuberculosis drug bedaquiline are now described. It now has been found that the compound bedaquiline can be formulated into micro- or nanoparticles and that such formulations can be used as long-acting (or depot) formulations, which may find use in the treatment of various bacterial infections, including e.g. tuberculosis.

Challenges for such formulations would have been thought to exist based on pharmacokinetic (PK) properties of tuberculosis drugs, including bedaquiline, and the need to keep plasma levels above a minimum level bearing those PK properties in mind. The mean terminal elimination half-life of bedaquiline and the N-monodesmethyl metabolite (also known as the M2 metabolite) is approximately 5.5 months. This long terminal elimination phase likely reflects slow release of bedaquiline and M2 from peripheral tissues. In October 2016 at the UNION conference in Liverpool Susan Swindells from the University of Nebraska Medical Center presented on “Experience from Long-Acting HIV Drug Development” where it was summarised that existing tuberculosis drugs were not ideal candidates (for long-acting) and reliable pharmacodynamic models were lacking.

It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.

An embodiment of the invention furthermore relates to the intermittent administration of these micro- or nanoparticle formulations at time intervals of one week or longer that result in plasma levels that may be sufficient to suppress the growth of the mycobacterial infection. This allows for a reduced number of administrations thereby being beneficial in terms of pill burden and drug compliance of the patient. The micro- or nanoparticle formulations of bedaquiline of the invention therefore may be useful in the long-term treatment of mycobacterial infections (e.g. tuberculosis, including latent tuberculosis, and leprosy).

The intermittent administration of micro- or nanoparticle formulations of bedaquiline at time intervals of one week or longer furthermore results in plasma levels that may be sufficient to provide prevention against transmission of mycobacterial infection. Also in this instance, a reduced number of administrations is required, which again is advantageous in terms of pill burden and drug compliance of the individual at risk of being infected.

Summary of the Invention

In a first aspect, the present invention provides a pharmaceutical composition for administration by intramuscular or subcutaneous injection, comprising a therapeutically effective amount of bedaquiline, or a pharmaceutically acceptable salt thereof, in the form of a suspension of micro- or nanoparticles comprising:

(a) bedaquiline, or a pharmaceutically acceptable salt thereof, in micro- or nanoparticle form, and a surface modifier; and

(b) a pharmaceutically acceptable aqueous carrier,

wherein such a composition may be referred to herein as “composition(s) of the invention”.

In a second aspect, the present invention provides use of a pharmaceutical composition as defined in the first aspect, in the manufacture of a medicament for the treatment of a pathogenic mycobacterial infection.

In a third aspect, the present invention provides a method of treating a pathogenic mycobacterial infection, comprising administering the pharmaceutical composition as defined in the first aspect, to a subject in need thereof.

In a fourth aspect, the present invention provides a process for preparing a pharmaceutical composition as defined in the first aspect, comprising

- (a) obtaining bedaquiline, or a pharmaceutically acceptable salt thereof, in micronized form;
- (b) adding the micronized bedaquiline, or a pharmaceutically acceptable salt thereof, to a liquid medium to form a premix/predispersion; and
- (c) subjecting the premix to mechanical means in the presence of a grinding medium to reduce the average effective particle size.

The composition of the invention is a suspension, by which we mean that the bedaquiline active ingredient is suspended in the pharmaceutically acceptable aqueous carrier.

The composition of the invention (i.e. the suspension) contains a surface modifier, which may be adsorbed onto the surface of the active ingredient bedaquiline.

In an embodiment, the present invention may therefore concern a pharmaceutical composition for administration by intramuscular or subcutaneous injection, comprising a therapeutically effective amount of bedaquiline, or a pharmaceutically acceptable salt thereof, in the form of a suspension of micro- or nanoparticles comprising:

- (a) bedaquiline, or a pharmaceutically acceptable salt thereof, in micro- or nanoparticle form, having a surface modifier adsorbed to the surface thereof; and
- (b) a pharmaceutically acceptable aqueous carrier; wherein the bedaquiline active ingredient is suspended.

The invention further concerns a method of treating a subject infected with pathogenic mycobacteria such as *Mycobacterium tuberculosis*, *M. bovis*, *M. leprae*, *M. avium* and *M. marinum*. In an embodiment, the mycobacteria is *Mycobacterium tuberculosis* (including the latent or dormant form) or *Mycobacterium leprae*. The compositions of the invention may be particularly suitable for the treatment of *Mycobacterium leprae* and the latent or dormant form of *Mycobacterium tuberculosis*. This is because for treating these specific infections, a lower concentration of bedaquiline in the plasma may be effective against such infection, for instance as described in Antimicrobial Agents and Chemotherapy, Sept 2009, p. 3989-3991 by Robert Gelber, Koen Andries *et al* (the contents of which are hereby incorporated by reference, and wherein, essentially, it is reported that low and intermittent dosing with bedaquiline holds promise for leprosy patients; whereas minimal dose killing 99% of bacilli for *M. tuberculosis* is 30 mg/kg/wk, for *M. leprae* it is < 5.0 mg/kg/wk, and hence dosing once a month may be as efficient as 5 days a week; other publications of the effect of bedaquiline on *Mycobacterium leprae* in mice include

Antimicrobial Agents and Chemotherapy, April 2006, p. 1558-1560 by Baohong Ji, Koen Andries *et al* – the contents of which are also hereby incorporated by reference). Hence, the compositions of the invention may be particularly suitable in a method of treating a subject infected with *Mycobacterium leprae* or the latent/dormant form of *Mycobacterium tuberculosis*. Such methods of treating a subject infected with pathogenic mycobacteria comprise the administration, by intramuscular or subcutaneous injection, of a therapeutically effective amount of a pharmaceutical composition as specified above or hereinafter. Or, alternatively, the invention concerns the use of a pharmaceutical composition as specified above or hereinafter, for the manufacture of a medicament for treating pathogenic mycobacteria infection (or for using such medicament in a particular treatment regime as described herein). In one embodiment, the composition is for the long-term treatment of pathogenic mycobacteria infection. In an embodiment, the pathogenic mycobacterial infection may such as described above or hereinafter, such as an infection that requires long-term treatment (in a further embodiment, an infection that further may be treated at relatively low plasma concentration levels of bedaquiline or its active metabolite, for instance latent/dormant *Mycobacterium tuberculosis* or, in a particular embodiment, *Mycobacterium leprae*).

In another embodiment, there is provided a method for the long term treatment of a subject infected with pathogenic mycobacteria such as *Mycobacterium tuberculosis*, *M. bovis*, *M. leprae*, *M. avium* and *M. marinum*, said method comprising the administration of an effective amount of a pharmaceutical composition as specified above or hereinafter, for administration by intramuscular or subcutaneous injection; wherein the composition is administered or is to be administered intermittently at a time interval that is in the range of one week to one year, or one week to two years. Or, alternatively, the invention concerns the use of a pharmaceutical composition as specified above or hereinafter, for the manufacture of a medicament for the long term treatment of a subject infected with pathogenic mycobacteria such as *Mycobacterium tuberculosis*, *M. bovis*, *M. leprae*, *M. avium* and *M. marinum*, for administration by intramuscular or subcutaneous injection, wherein the composition is administered or is to be administered intermittently at a time interval that is in the range of one week to one year, or one week to two years. Hence, it will be understood that the term “long term treatment” refers to treatment where one dose or one administration (e.g. by intramuscular or subcutaneous injection) will have a persistent therapeutic effect over a time period, as described herein, for instance a persistent therapeutic effect over several hours, weeks or months (e.g. in an embodiment, over a period of at least or up to one month, three months or six months); see examples. Put another way, long term treatment may refer to, where there is more than one

dose/administration, the long period of time (as described herein) between the doses/administrations, i.e. the intervals are a long period of time as described herein.

In another embodiment, there is provided a method for the long term treatment of a subject infected with pathogenic mycobacteria (e.g. of any of the types as described here), as described herein (e.g. above) wherein one dose or administration (e.g. of the amount described herein, e.g. hereinafter) is provided/required (and has a persistent effect, e.g. over a time period described herein). In another embodiment, there is provided such a long term treatment regime, where two such doses or administrations are provided/required, which doses/administrations are given at intervals, wherein the interval time period is that as described herein, e.g. a period of at least or up to one month, three months or six months – for instance for a period of time in which persistent therapeutic effect lasts). In a further embodiment, there is provided such a long term treatment regime, in which three such doses or administrations are provided/required at such intervals as herein described. In yet a further embodiment, there is provided a long term treatment regime as herein described but which is preceded with a lead-in treatment phase (that is not a long term treatment regime, e.g. a once-daily administration course, lasting for one week, two weeks, three weeks or one month).

The invention further concerns a method for the prevention of a pathogenic mycobacterial infection in a subject at risk of being infected by a pathogenic mycobacterial infection, said method comprising administering an amount, effective in preventing a pathogenic mycobacterial infection, of a pharmaceutical composition as specified above or as further specified hereinafter, to said subject. Or alternatively, the invention concerns the use of a pharmaceutical composition as specified above or as further specified hereinafter for the manufacture of a medicament for the prevention of a pathogenic mycobacterial infection in a subject at risk of being infected by a pathogenic mycobacterial infection.

In another embodiment the invention relates to a method for the long term prevention of a pathogenic mycobacterial infection in a subject at risk of being infected by a pathogenic mycobacterial infection, said method comprising administering to said subject an effective amount of a pharmaceutical composition as specified above or as further specified hereinafter, wherein the composition is administered or is to be administered intermittently at a time interval that is in the range of one week to one year, or one week to two years.

The present invention furthermore relates to the use of a pharmaceutical composition as specified above or as further specified hereinafter, for the manufacture of a medicament for the long term prevention for the long term prevention of a pathogenic mycobacterial infection in a subject at risk of being infected by a pathogenic mycobacterial infection, wherein the composition is administered or is to be administered intermittently at a time interval that is in the range of one week to one year or one week to two years.

In one embodiment the invention concerns a use or a method as specified herein, wherein the pharmaceutical composition is administered or is to be administered at a time interval that is in the range of one week to one month, or in the range of one month to three months, or in the range of three months to six months, or in the range of six months to twelve months, or in the range of 12 months to 24 months.

In another embodiment the invention concerns a use or a method as specified herein, wherein the pharmaceutical composition is administered or is to be administered once every two weeks, or once every month, or once every three months.

Further pharmaceutical compositions, methods of treatment or prevention, as well as uses for the manufacture of medicaments based on these compositions will be described hereinafter and are meant to be part of the present invention.

Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise”, “comprising”, and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”.

The invention is also described with reference to the following figures:

Figure 1: “Plasma kinetics of TMC207 (bedaquiline; BDQ) and M2 (bedaquiline’s metabolite; see herein) in mouse, after a single dose of 30 mg/kg”

Figure 2: “Plasma kinetics of TMC207 in mouse when administered IM or SC with 200 mg/ml formulations (specifically formulations of Examples 1A and 1B, i.e. the nano- and micro-suspension, respectively) at a dose of 160 mg/kg” (TMC207 is referred to in the Figure as “UD”)

Figure 3: “Plasma kinetics of M2 in mouse when administered IM or SC with 200 mg/ml formulations (specifically formulations of Examples 1A and 1B, i.e. the nano- and micro-suspension, respectively) at a dose of 160 mg/kg” (M2 is referred to in the Figure as “met”)

Figure 4: “Plasma kinetics of TMC207 in mouse when administered IM or SC with 100 mg/ml formulations (specifically formulations of Examples 1C and 1D, i.e. the nano- and micro-suspension, respectively) at a dose of 80 mg/kg” (TMC207 is referred to in the Figure as “UD”)

Figure 5: “Plasma kinetics of M2 in mouse when administered IM or SC with 100 mg/ml formulations (specifically formulations of Examples 1C and 1D, i.e. the nano- and micro-suspension, respectively) at a dose of 80 mg/kg” (M2 is referred to in the Figure as “met”)

Figure 6: “Plasma kinetics of TMC207 in male rats when administered IM or SC with 200 mg/ml micro-formulation (see Example 1, Formulation 1B i.e. the micro-suspension) at a dose of 40 mg/kg” and “Plasma kinetics of TMC207 in male rats when administered IM or SC with 200 mg/ml nano-formulation (see Example 1, Formulation 1A, i.e. the nano-suspension) at a dose of 40 mg/kg”

Figure 7: “Plasma kinetics of TMC207 in male beagle dogs when administered IM or SC with 200 mg/ml micro-formulation (see Example 1, Formulation 1B) at a dose of 40 mg/kg” and “Plasma kinetics of TMC207 in male beagle dogs when administered IM or SC with 200 mg/ml nano-formulation (see Example 1, Formulation 1A) at a dose of 40 mg/kg”

Detailed Description of the Invention

The compound used in the invention is the compound TMC207, also referred to as bedaquiline.

5 Bedaquiline can be used in its non-salt form or as a suitable pharmaceutically acceptable salt form, such as an acid addition salt form or base addition salt form. In an embodiment, bedaquiline is in its non-salt form in compositions of the invention.

10 The pharmaceutically acceptable acid addition salts are defined to comprise the therapeutically active non-toxic acid addition salt forms which bedaquiline is able to form. Said acid addition salts can be obtained by treating the free form of bedaquiline with appropriate acids, for example inorganic acids, for example hydrohalic acid, in particular hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid ; organic acids, for example acetic acid, hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclamic acid, salicyclic acid, p-aminosalicylic acid and pamoic acid. In particular, the fumarate salt is considered, given that this is the form employed in the already-marketed product Sirturo®.

15 20 Possible therapeutically active non-toxic base addition salt forms may be prepared by treatment with appropriate organic and inorganic bases. Appropriate base salts forms comprise, for example, the ammonium salts, the alkaline and earth alkaline metal salts, in particular lithium, sodium, potassium, magnesium and calcium salts, salts with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, hybramine salts, and salts with amino acids, for example arginine and lysine.

25 Conversely, said acid or base addition salt forms can be converted into the free forms by treatment with an appropriate base or acid.

30 35 The term addition salt as used in the framework of this application also comprises the solvates which bedaquiline as well as the salts thereof, are able to form. Such solvates are, for example, hydrates and alcoholates.

40 Whenever reference to bedaquiline (or TMC207) is employed herein, we refer to the single stereoisomeric form that is employed in the marketed product Sirturo®, and which is disclosed in WO2004/011436 as an antimycobacterial agent.

It has been found that the physico-chemical properties of bedaquiline allow for the manufacture of micro- or nanoparticle suspensions that have unique pharmacokinetic properties in that they can be used for the long term treatment of a pathogenic

5 mycobacterial infection as well as in the long term prevention of a pathogenic mycobacterial infection and to this purpose only a limited number of drug administrations is required. This is beneficial in terms of pill-burden as well as patient compliance with the prescribed dose regimen.

10 As used herein the term “treatment of a pathogenic mycobacterial infection” relates to the treatment of a subject being infected with a pathogenic mycobacterial infection.

The term “prevention of a pathogenic mycobacterial infection” relates to the prevention or avoidance of a subject becoming infected with a pathogenic mycobacterial infection.

15 The source of infection can be various, for instance a material containing a pathogenic mycobacterial infection.

The terms “therapeutically effective amount”, “an amount, effective in preventing a pathogenic mycobacterial infection”, and similar terms, refer to amounts, or

20 concentrations, of the compositions of the invention (or amounts/concentrations of active ingredient bedaquiline within such compositions) that result in efficacious plasma levels. With “efficacious plasma levels” it is meant those plasma levels of bedaquiline that provide effective treatment or effective prevention of a pathogenic mycobacterial infection. This is because amount/dose/administration given may be
25 linked to the desired exposure levels or desired plasma levels for the effective treatment/prevention, for instance as described herein (see e.g. the examples).

The term “subject” in particular relates to a human being.

30 The term “micro- or nanoparticles” refers to particles in the micrometer or nanometer range. The size of the particles should be below a maximum size above which administration by subcutaneous or intramuscular injection becomes impaired or is even no longer possible. Said maximum size depends for example on the limitations imposed by the needle diameter or by adverse reactions of the body to large particles, or both.

35 In one embodiment, the pharmaceutical compositions of the invention comprise bedaquiline in microparticle form. In another embodiment, the pharmaceutical compositions of the invention comprise bedaquiline in nanoparticle form.

The average effective particle size of the micro- or nanoparticles of the present invention may be below about 50 μm , or below about 20 μm , or below about 10 μm , or below about 1000 nm, or below about 500 nm, or below about 400 nm, or below about 300 nm, or below about 200 nm. The lower limit of the average effective particle size 5 may be low, e.g. as low as about 100 nm or as low as about 50 nm. In one embodiment, the average effective particle size is in the range of about 50 nm to about 50 μm , or about 50 nm to about 20 μm , or about 50 nm to about 10 μm , or about 50 nm to about 1000 nm, about 50 nm to about 500 nm, or about 50 nm to about 400 nm, or about 10 50 nm to about 300 nm, or about 50 nm to about 250 nm, or about 100 nm to about 250 nm, or about 150 nm to about 220 nm, or 100 to 200 nm, or about 150 nm to about 200 nm, e.g. about 130 nm, or about 150 nm. For instance, both after preparation and 15 after a period of time of up to 3 months (e.g. when stored at temperatures of about 5°C, 25°C and 40°C) generally:

- the micro-suspensions may have, in an embodiment, a D90 of between about 15 3 and 10 μm (e.g. about 3.5, 4 or 5 μm) and a D50 of between about 2 and 4 μm (e.g. about 3 μm)
- the nano-suspensions may have, in an embodiment, a D90 of between about 0.5 and 1.5 μm (e.g. about, or less than 1 μm or about, or less than about 1000 nm) and a D50 of between about 0.1 and 0.5 μm (e.g. about, or less than, about 20 0.3 μm , or less than about 300 nm).

In an embodiment, the micro-particles are employed, wherein the average effective particle size, as measured by D10, D50 and/or D90 (in an embodiment as measured by D50) is below about 50 μm , or below about 20 μm , and above about 0.1 μm (100 nm). 25 In an embodiment the range for such micro-particles employed in the compositions of the invention is between about 20 μm and about 0.1 μm (in a further embodiment between about 15 μm , and above about 0.2 μm (200 nm) and in a further embodiment between about 10 μm , and above 0.5 μm (500 nm), for instance between about 10 μm , and above 1 μm or below about 1000 nm, or below about 500 nm, or below about 30 400 nm, or below about 300 nm, or below about 200 nm. The foregoing values are refer to measurements after preparation. They may also, however, in an embodiment, refer to measurements after a period of time up to 3 months (e.g. after 5 days, one week, two weeks, one month, two months or three months) and stored at various temperatures (e.g. at temperatures of about 5°C, 25°C and 40°C). 35

As used herein, the term average effective particle size has its conventional meaning as known to the person skilled in the art and can be measured by art-known particle size

measuring techniques such as, for example, sedimentation field flow fractionation, photon correlation spectroscopy, laser diffraction or disk centrifugation. The average effective particle sizes mentioned herein may be related to volume distributions of the particles. In that instance, by "an effective average particle size of less than about

5 50 μm " it is meant that at least 50% of the volume of the particles has a particle size of less than the effective average of 50 μm , and the same applies to the other effective particle sizes mentioned. In a similar manner, the average effective particle sizes may be related to weight distributions of the particles but usually this will result in the same or about the same value for the average effective particle size.

10

The pharmaceutical compositions of the present invention provide release of the active ingredient bedaquiline over a prolonged period of time and therefore they can also be referred to as sustained or delayed release compositions. After administration, the compositions of the invention stay in the body and steadily release bedaquiline, keeping 15 such levels of this active ingredient in the patient's system for a prolonged period of time, thereby providing, during said period, the appropriate treatment or prevention of a pathogenic mycobacterial infection. Because of the fact that the pharmaceutical compositions of the invention stay in the body and steadily release bedaquiline (and its active metabolite, referred to as M2 herein; see hereinafter, the methyl-substituted 20 metabolite), they can be referred to as pharmaceutical compositions suitable as long-acting (or depot) formulations.

As used herein with the term "prolonged period of time", there is meant a term (or time period) that may be in the range of one week up to one year or up to two years, or a

25 term in the range of one to two weeks, or two to three weeks, or three to four weeks, or a term in the range of one to two months, or two to three months, or three to four months, or three to six months, or six months to 12 months, or 12 months to 24 months, or a term that is in the range of several days, e.g. 7, 10 or 12 days, or several weeks, e.g. 2, 3 or 4 weeks, or one month, or several months, e.g. 2, 3, 4, 5 or six months or 30 even longer, e.g. 7, 8, 9 or 12 months.

The pharmaceutical compositions of this invention may be applied in the long-term treatment or the long-term prevention of a pathogenic mycobacterial infection, or with other words they may be used in the treatment of a pathogenic mycobacterial infection, 35 or in the prevention of a pathogenic mycobacterial infection, during a prolonged period of time. The compositions of the invention are effective in the treatment or prevention of a pathogenic mycobacterial infection for a prolonged period of time, for example for

at least about one week or longer, or for about 1 month or longer. By the expression "effective for at least about one week or longer", one means that the plasma level of the active ingredient, bedaquiline (and/or its active metabolite M2), should be above a threshold value. In case of therapeutic application said threshold value is the lowest 5 plasma level at which bedaquiline (and/or its active metabolite M2) provides effective treatment of a pathogenic mycobacterial infection. In case of application in the prevention of a pathogenic mycobacterial infection said threshold value is the lowest plasma level at which bedaquiline (and/or its active metabolite M2) is effective in preventing transmission of a pathogenic mycobacterial infection.

10

With "long term" for example as used in relation to "long term prevention of a pathogenic mycobacterial infection" or "long term treatment of a pathogenic mycobacterial infection", or similar terminology, there are meant terms that may be in the range of one week up to one year or up to two years, or longer, such as five or

15

10 years. In particular in the case of treatment of a pathogenic mycobacterial infection, such terms will be long, in the order of one to several months, one year or longer. Such terms may also be relatively short, in particular in the case of prevention. Shorter terms are those of several days, e.g. 7, 10 or 12 days, or several weeks, e.g. 2, 3 or 4 weeks, or one month, or several months, e.g. 2, 3, 4, 5 or six months or even longer, e.g. 7, 8, 9 20 or 12 months. In one embodiment the methods and uses in accordance with the present invention are for the prevention of a pathogenic mycobacterial infection during one month, or several months, e.g. 2, 3, 4, 5 or six months or even longer, e.g. 7, 8, 9 or 12 months.

25

The pharmaceutical compositions of the present invention can be administered at various time intervals. When used in the prevention of a pathogenic mycobacterial infection, the pharmaceutical compositions of this invention can be administered only once or a limited number of times such as twice, three, four, five or six times, or more. This may be recommendable where prevention is required during a limited period of 30 time, such as the period during which there is a risk of infection.

The pharmaceutical compositions of the present invention can be administered at the time intervals mentioned above, such as at a time interval that is in the range of one week to one month, or in the range of one month to three months, or in the range of 35 three months to six months, or in the range of six months to twelve months. In one embodiment, the pharmaceutical composition can be administered once every two weeks, or once every month, or once every three months. In another embodiment the

- time interval is in the range of one to two weeks, or two to three weeks, or three to four weeks, or the time interval is in the range of one to two months, or two to three months, or three to four months, or three to six months, or six months to 12 months, or 12 months to 24 months. The time interval may be at least one week, but may also be 5 several weeks, e.g. 2, 3, 4, 5 or 6 weeks, or at time intervals of one month, or of several months, e.g. 2, 3, 4, 5 or 6 months or even longer, e.g. 7, 8, 9 or 12 months. In one embodiment, the pharmaceutical compositions of the present invention are administered at a time interval of one, two or three months. These longer periods between each administration of the pharmaceutical compositions of the invention 10 provide further improvements in terms of pill burden and compliance. To further improve compliance, patients can be instructed to take their medication at a certain day of the week, where the composition is administered on a weekly schedule, or at a certain day of the month in case of a monthly schedule.
- 15 The length of the time intervals between each administration of a composition of the present invention may vary. For example said time intervals may be selected in function of the plasma levels. The intervals may be shorter where the plasma levels of bedaquiline (and/or its active metabolite M2) are deemed too low, e.g. when these approach the minimum plasma level specified hereinafter. The intervals may be longer 20 where the plasma levels of bedaquiline (and/or its active metabolite M2) are deemed too high. In one embodiment, the compositions of the invention are administered at equal time intervals. The compositions may be administered without any interjacent additional administrations, or with other words, the compositions may be administered at particular points in time separated from one another by a time period of varying or 25 equal length, e.g. a time period of at least one week, or any other time period specified herein, during which no further bedaquiline is administered. Having time intervals of the same length has the advantage that the administration schedule is simple, e.g. administration takes place at the same day in the week, or the same day in the month. Such administration schedule therefore involves limited “pill burden” thereby 30 contributing beneficially to the patient’s compliance to the prescribed dosing regimen.

35 The concentration (or “C”) of bedaquiline (and/or its active metabolite M2) in the plasma of a subject treated therewith is generally expressed as mass per unit volume, typically nanograms per milliliter (ng/ml). For convenience, this concentration may be referred to herein as “plasma drug concentration” or “plasma concentration”.

The dose (or amount) of bedaquiline administered, depends on the amount of bedaquiline in the pharmaceutical compositions of the invention, or on the amount of a given composition that is administered. Where higher plasma levels are desired, either or both of a composition of higher bedaquiline concentration, or more of a given 5 composition, may be administered. This applies vice versa if lower plasma levels are desired. Also a combination of varying time intervals and varying dosing may be selected to attain certain desired plasma levels.

10 The dose (or amount) of bedaquiline administered also depends on the frequency of the administrations (i.e. the time interval between each administration). Usually, the dose will be higher where administrations are less frequent. All these parameters can be used to direct the plasma levels to desired values

15 The dosing regimen also depends on whether prevention or treatment of the pathogenic mycobacterial infection is envisaged. In case of therapy, the dose of bedaquiline administered or the frequency of dosing, or both, are selected so that the plasma concentration of bedaquiline is kept above a minimum plasma level. The term “minimum plasma level” (or C_{min}) in this context refers to the plasma level of bedaquiline (and/or its active metabolite M2) that provides effective treatment of the 20 pathogenic mycobacterial infection. In particular, the plasma level of bedaquiline (and/or its active metabolite M2) is kept at a level above a minimum plasma level of about 10 ng/ml, or above about 15 ng/ml, or above about 20 ng/ml, or above about 40 ng/ml. The plasma level of bedaquiline (and/or its active metabolite M2) may be kept above a minimum plasma level that is higher, for example above about 50 ng/ml, 25 or above about 90 ng/ml, or above about 270 ng/ml, or above about 540 ng/ml. In one embodiment, the plasma level of bedaquiline (and/or its active metabolite M2) is kept above a level of about 13.5 ng/ml, or is kept above a level of about 20 ng/ml. Or the plasma level of bedaquiline (and/or its active metabolite M2) may be kept within certain ranges, in particular ranges starting from a minimum plasma level selected from 30 those mentioned above and ending at a higher plasma levels selected from those mentioned above and selected from 500 ng/ml and 1000 ng/ml (e.g. from 10 to 15, 10 to 20, 10 to 40, etc., or from 15 to 20, or 15 to 40, or 15 to 90, etc., or 20 to 40, 20 to 90, or 20 to 270, etc., or 40 to 90, 40 to 270, or 40 -540, etc., each time from about the indicated value in ng/ml to about the indicated value in ng/ml). In one embodiment said 35 range is from about 10 to about 20, from about 20 to about 90, from 90 to 270, from 270 to 540, from 540 to 1000, each time from about the indicated value in ng/ml to about the indicated value in ng/ml.

The plasma levels of bedaquiline (and/or its active metabolite M2) should be kept above the above-mentioned minimum plasma levels because at lower levels the bacteria may no longer be sufficiently suppressed so that it can multiply with the 5 additional risk of the emergence of mutations.

In the instance of prevention, the term “minimum plasma level” (or C_{min}) refers to the lowest plasma level of bedaquiline (and/or its active metabolite M2) that provides effective treatment/prevention of infection.

10

In particular, in the instance of prevention, the plasma level of bedaquiline (and/or its active metabolite M2) can be kept at a level above a minimum plasma level mentioned above in relation to therapy. However in prevention the plasma level of bedaquiline (and/or its active metabolite M2) can be kept at a lower level, for example at a level 15 above about 4 ng/ml, or about 5 ng/ml, or about 8 ng/ml. The plasma levels of bedaquiline (and/or its active metabolite M2) should preferably be kept above these minimum plasma levels because at lower levels the drug may no longer be effective thereby increasing the risk of transmission of infection. Plasma levels of bedaquiline (and/or its active metabolite M2) may be kept at somewhat higher levels to have a 20 safety margin. Such higher levels start from about 50 ng/ml or more. The plasma level of bedaquiline (and/or its active metabolite M2) can be kept at a level that is in the ranges mentioned above in relation to therapy, but where the lower limits include the plasma levels of about 4 ng/ml, or about 5 ng/ml, or about 8 ng/ml.

25 An advantage of bedaquiline (and/or its active metabolite M2) is that it may be used up to relatively high plasma levels without any significant side effects. The plasma concentrations of bedaquiline (and/or its active metabolite M2) may reach relatively high levels, but as with any drug should not exceed a maximum plasma level (or C_{max}), which is the plasma level where bedaquiline (and/or its active metabolite M2) causes 30 significant side effects. Additionally, compound-release from the tissue should also be taken into account, which is not counted for within plasma levels. As used herein, the term “significant side effects” means that the side effects are present in a relevant patient population to an extend that the side effects affect the patients’ normal functioning. In an embodiment, the amount and the frequency of administrations of 35 bedaquiline (and/or its active metabolite M2) to be administered are selected such that the plasma concentrations are kept during a long term at a level comprised between a

maximum plasma level (or C_{\max} as specified above) and a minimum plasma level (or C_{\min} as specified above).

In certain instances it may be desirable to keep the plasma levels of bedaquiline (and/or its active metabolite M2) at relatively low levels, e.g. as close as possible to the minimum plasma levels specified herein. This will allow reducing the frequency of the administrations and/or the quantity of bedaquiline (and/or its active metabolite M2) administered with each administration. It will also allow avoiding undesirable side effects, which will contribute to the acceptance of the dosage forms in most of the targeted population groups who are healthy people at risk of being infected and therefore are less inclined to tolerate side effects. The plasma levels of bedaquiline (and/or its active metabolite M2) may be kept at relatively low levels in the instance of prevention. One embodiment concerns uses or methods for prevention of infection, as specified above or hereinafter, wherein the minimum plasma level of bedaquiline (and/or its active metabolite M2) is as specified herein and the maximum plasma level is about equal to the lowest plasma level that causes the active ingredient to act therapeutically, also as specified herein.

In other embodiments, the plasma level of bedaquiline (and/or its active metabolite M2) is kept at a level below a lower maximum plasma level of about 10 ng/ml, more in particular about 15 ng/ml, further in particular about 20 ng/ml, still more in particular about 40 ng/ml. In a particular embodiment, the plasma level of bedaquiline (and/or its active metabolite M2) is kept below a level of about 13.5 ng/ml. In one embodiment, the plasma level of bedaquiline (and/or its active metabolite M2) is kept in an interval of the lower maximum blood level specified above, and the minimum plasma levels mentioned in relation to prevention. For example the plasma levels of bedaquiline (and/or its active metabolite M2) are kept below about 10 ng/ml and above a minimum level of about 4 ng/ml.

In other instances it may be desirable to keep the plasma levels of bedaquiline (and/or its active metabolite M2) at relatively higher levels, for example where there is a high risk of infection and more frequent and/or higher doses are not an issue. In these instances the minimum plasma level may be equal to the lowest plasma level of bedaquiline (and/or its active metabolite M2) that provides effective treatment of a pathogenic mycobacterial infection, such as the specific levels mentioned herein.

In the instance of prevention, the dose to be administered should be calculated on a basis of about 0.2 mg/day to about 50 mg/day, or 0.5 mg/day to about 50 mg/day, or of about 1 mg/day to about 10 mg/day, or about 2 mg/day to about 5 mg/day, e.g. about 3 mg/day. This corresponds to a weekly dose of about 1.5 mg to about 350 mg, in particular of about 3.5 mg to about 350 mg, in particular of about 7 mg to about 70 mg, or about 14 mg to about 35 mg, e.g. about 35 mg, or to a monthly dose of from 6 mg to about 3000 mg, in particular about 15 mg to about 1,500 mg, more in particular of about 30 mg to about 300 mg, or about 60 mg to about 150 mg, e.g. about 150 mg. Doses for other dosing regimens can readily be calculated by multiplying the daily dose with the number of days between each administration.

In the instance of therapy, the dose to be administered should be somewhat higher and should be calculated on a basis of about 1 mg/day to about 150 mg/day, or of about 2 mg/day to about 100 mg/day, or of about 5 mg/day to about 50 mg/day, or about 10 mg/day to about 25 mg/day, e.g. about 15 mg/day. The corresponding weekly or monthly doses can be calculated as set forth above. For applications in prevention, the doses may be lower although the same dosing as for therapeutic applications may be used. In an embodiment, the dose/administration is given at monthly intervals or three-monthly or six-monthly intervals, with the total treatment duration being three, six or 20 12 months. In the instances where the dose/administration is monthly, three monthly or six-monthly, in an embodiment, the dose given (e.g. in human subjects) is calculated on the basis of a 400 mg daily dose given for 2 weeks. Hence, the total amount of bedaquiline given per dose may be about 5600 mg (e.g. in the range of 3000 and 8000 mg), but it may be up to one fifth of such an amount (e.g. in the range of 500 and 25 2000 mg, e.g. between about 1000 and 1500 mg).

In another embodiment, in the case of prevention or in particular therapy, the doses may also be expressed in mg/kg. For instance, in the examples, certain doses may be administered based on weight (of e.g. the mammal, and as shown in the examples here, 30 in mouse) and hence doses between 1 mg/kg and 1000 mg/kg may be employed (e.g. 40 mg/kg, 80 mg/kg, 160 mg/kg, 320 mg/kg or 480 mg/kg may be employed) and such doses may remain effective for a period of 4 weeks, 8 weeks or 12 weeks (for example as shown in the examples). For instance, one dose may be taken every 4 weeks (effectively seen as a 12 week treatment regimen, i.e. three doses in total) or one single 35 dose may be taken, which effectively provides sufficient treatment (e.g. as defined by reduction in CFUs, see examples) as may be evidenced by monitoring over a 12 week period. Hence, in an aspect, in order to treat the bacterial infection one dose may be

taken (e.g. between 1 mg/kg and 1000 mg/kg, for instance between 2 mg/kg and 500 mg/kg) or one such dose may be taken every 4 weeks (e.g. two or three such doses may be taken). Such dose depends on the bacterial infection to be treated. For instance, in the treatment of latent tuberculosis or leprosy, lower doses may be required 5 (compared to e.g. multi-drug resistant tuberculosis) given that a lower amount of bedaquiline is required to control the bacteria. An example of this is described hereinafter (Example 3), wherein it is indicated that in mice one dose of 160 mg/kg may sufficiently reduce CFUs in the mouse model of latent tuberculosis infection – it was also seen that two or three doses of 160 mg/kg (the second and the third doses 10 administered at 4 and 8 weeks, respectively) were also effective in that model.

It has been found that, once administered, the plasma levels of bedaquiline (and/or its active metabolite M2) are more or less stable, i.e. they fluctuate within limited margins. The plasma levels have been found to approach more or less a steady state mode or to 15 approximate more or less a zero order release rate during a prolonged period of time. By “steady state” is meant the condition in which the amount of drug present in the plasma of a subject stays at more or less the same level over a prolonged period of time. The plasma levels of bedaquiline (and/or its active metabolite M2) generally do not show any drops below the minimum plasma level at which the drug is effective. 20 The term “stays at more or less the same level” does not exclude that there can be small fluctuations of the plasma concentrations within an acceptable range, e.g. fluctuations within a range of about $\pm 30\%$, or about $\pm 20\%$, or about $\pm 10\%$, or about $\pm 10\%$.

25 In some instances there may be an initial plasma concentration peak after administration, after which the plasma levels achieve a “steady-state”, as mentioned hereinafter.

30 The compositions of the invention show good local tolerance and ease of administration. Good local tolerance relates to minimal irritation and inflammation at the site of injection; ease of administration refers to the size of needle and length of time required to administer a dose of a particular drug formulation. In addition, the compositions of the invention show good stability and have an acceptable shelf life.

35 The micro- or nanoparticles of the present invention have a surface modifier adsorbed on the surface thereof. The function of the surface modifier is to act as a wetting agent as well as a stabilizer of the colloidal suspension.

In one embodiment, the micro- or nanoparticles in the compositions of the invention mainly comprise crystalline bedaquiline or a salt thereof; and a surface modifier, the combined amount of which may at least comprise about 50%, or at least about 80%, or at least about 90%, or at least about 95%, or at least about 99% of the micro- or nano particles. As indicated herein, in an embodiment, bedaquiline is in its non-salt form (or in its “free form”) and in a further embodiment it is in a crystalline non-salt (or free) form. In this respect, as mentioned herein, bedaquiline may be prepared as such using the procedures described in international patent application WO 2004/011436 (or in WO 2006/125769, which describes an optical resolution with a chiral reagent).

- 5 10 Following such procedure, the bedaquiline is obtained by precipitation from toluene/ethanol and it is indicated that the product crystallises. Such form of bedaquiline may be used in the preparation of the compositions of the invention and, further, such form may be a single crystalline polymorph with the following characterising features:
- 15 (i) a melting endotherm at 181.5°C (endotherm onset) and DSC curve showing melting of the product at about 182.5°C (immediately followed by decomposition; measured by differential scanning calorimetry (DSC) by transfer of about 3 mg of compound into a standard aluminum TA-Instrument sample pan, sample pan closed with the appropriate cover and DSC curve recorded on a TA-Instruments Q2000 MTDSC equipped with a RCS cooling unit using the following parameters – initial temperature 25°C; heating range 10°C/min; final temperature 300°C, nitrogen flow 50 ml/min);
- 20 (ii) infrared (IR) spectrum peaks at *inter alia* about 1600 cm⁻¹, about 1450 cm⁻¹, about 1400 cm⁻¹, about 1340 cm⁻¹, and about 1250 cm⁻¹ (where a sample is analysed using a suitable microATR accessory deploying 32 scans, 1 cm⁻¹ resolution, Thermo Nexus 670 FTIR spectrometer, a DTGS with KBr windows detector, Ge on KBr beamsplitter and a micro ATR accessory (Harrick Split Pea with Si crystal); and/or
- 25 (iii) X-ray powder diffraction (XRPD) with characteristic peaks at about 11.25° 2-Theta, about 18° 2-Theta, about 18.5° 2-Theta, about 19° 2-Theta, about 20.25° 2-Theta, about 21.25° 2-Theta, about 22.25° 2-Theta, about 24.5° 2-Theta and about 27° 2-Theta, showing diffraction peaks without the presence of a halo indicating crystallinity of the product (where the analysis was carried out on a PANalytical (Philips) X’PertPRO MPD diffractometer, and the instrument is equipped with a Cu LFF X-ray tube and the compound was spread on a zero background sample holder; the Instrument Parameters were: generator voltage – 45 kV; generator amperage – 40 mA; geometry – Bragg-30
- 35

Brentano; stage – spinner stage; scan mode – continuous; scan range 3 to 50° 2θ; step size 0.02°/step; counting time 30 sec/step; spinner revolution time – 1 sec; radiation type CuKα).

Hence, in an embodiment, the bedaquiline employed in a process to prepare 5 compositions of the invention (i.e. before conversion to micro/nano-particles) is a crystalline form (e.g. of the specific form characterised above). In a further embodiment of the invention, the bedaquiline employed in the compositions of the invention (i.e. after conversion to micro/nano-particles, for instance by milling) is also in a crystalline form (e.g. of the specific form characterised above).

10

In a further aspect, the present invention is concerned with a pharmaceutical composition for administration by intramuscular or subcutaneous injection, comprising a therapeutically effective amount of bedaquiline, or a pharmaceutically acceptable salt thereof, in the form of a suspension of particles consisting essentially of:

- 15 (1) bedaquiline, or a pharmaceutically acceptable salt thereof in micro- or nanoparticle form, having a surface modifier adsorbed to the surface thereof; and
(2) a pharmaceutically acceptable aqueous carrier; wherein the active ingredient is suspended.
- 20 Suitable surface modifiers can be selected from known organic and inorganic pharmaceutical excipients, including various polymers, low molecular weight oligomers, natural products and surfactants. Particular surface modifiers include nonionic and anionic surfactants. Representative examples of surface modifiers include gelatin, casein, lecithin, salts of negatively charged phospholipids or the acid form 25 thereof (such as phosphatidyl glycerol, phosphatidyl inosite, phosphatidyl serine, phosphatic acid, and their salts such as alkali metal salts, e.g. their sodium salts, for example egg phosphatidyl glycerol sodium, such as the product available under the tradename Lipoid™ EPG), gum acacia, stearic acid, benzalkonium chloride, polyoxyethylene alkyl ethers, e.g., macrogol ethers such as cetomacrogol 1000, 30 polyoxyethylene castor oil derivatives; polyoxyethylene stearates, colloidal silicon dioxide, sodium dodecylsulfate, carboxymethylcellulose sodium, bile salts such as sodium taurocholate, sodium desoxytaurocholate, sodium desoxycholate; methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, magnesium aluminate silicate, polyvinyl alcohol (PVA), poloxamers, 35 such as Pluronic™ F68, F108 and F127 which are block copolymers of ethylene oxide and propylene oxide; tyloxapol; Vitamin E-TGPS (α-tocopheryl polyethylene glycol succinate, in particular α-tocopheryl polyethylene glycol 1000 succinate); poloxamines,

such as TetronicTM 908 (T908) which is a tetrafunctional block copolymer derived from sequential addition of ethylene oxide and propylene oxide to ethylenediamine; dextran; lecithin; dioctyl ester of sodium sulfosuccinic acid such as the products sold under the tradename Aerosol OTTM (AOT); sodium lauryl sulfate (DuponolTM P); alkyl aryl polyether sulfonate available under the tradename TritonTM X-200; polyoxyethylene sorbitan fatty acid esters (TweensTM 20, 40, 60 and 80); sorbitan esters of fatty acids (SpanTM 20, 40, 60 and 80 or ArlacelTM 20, 40, 60 and 80); polyethylene glycols (such as those sold under the tradename CarbowaxTM 3550 and 934); sucrose stearate and sucrose distearate mixtures such as the product available under the tradename 5 CrodestaTM F110 or CrodestaTM SL-40; hexyldecyl trimethyl ammonium chloride (CTAC); polyvinylpyrrolidone (PVP). If desired, two or more surface modifiers can be 10 used in combination.

Particular surface modifiers are selected from poloxamers, α -tocopheryl polyethylene 15 glycol succinates, polyoxyethylene sorbitan fatty acid esters, and salts of negatively charged phospholipids or the acid form thereof. More in particular the surface modifiers are selected from PluronicTM F108, Vitamin E TPGS, TweenTM 80, and LipoidTM EPG (and, in a particular embodiment, it is Vitamin E TPGS). One or more of these surface modifiers may be used. PluronicTM F108 corresponds to poloxamer 338 20 and is the polyoxyethylene, polyoxypropylene block copolymer that conforms generally to the formula HO-[CH₂CH₂O]_x-[CH(CH₃)CH₂O]_y-[CH₂CH₂O]_z-H in which the average values of x, y and z are respectively 128, 54 and 128. Other commercial 25 names of poloxamer 338 are Hodag NonionicTM 1108-F and SynperonicTM PE/F108. In one embodiment, the surface modifier comprises a combination of a polyoxyethylene sorbitan fatty acid ester and a phosphatidyl glycerol salt (in particular egg phosphatidyl glycerol sodium).

The optimal relative amount of bedaquiline in relation to the surface modifier depends 30 on the surface modifier selected, the specific surface area of the bedaquiline suspension which is determined by the average effective particle size and the bedaquiline concentration, the critical micelle concentration of the surface modifier if it forms micelles, etc. The relative amount (w/w) of bedaquiline to the surface modifier preferably is in the range of 1 : 2 to about 20 : 1, in particular in the range of 1 : 1 to about 10 : 1, e.g. about 4 : 1.

35

The particles of this invention can be prepared by means of micronization/particle size reduction/nanonization by mechanical means and by controlled precipitation from a

supersaturated solution, or by using supercritical fluids such as in the GAS technique (“gas anti-solvent”), or any combination of such techniques. In one embodiment a method is used comprising the steps of dispersing bedaquiline in a liquid dispersion medium and applying mechanical means in the presence of grinding media to reduce the particle size of bedaquiline to an average effective particle size of less than about 50 μm , in particular less than about 1,000 nm. The particles can be reduced in size in the presence of a surface modifier.

A general procedure for preparing the particles of this invention comprises

- 10 (a) obtaining bedaquiline in micronized form;
- (b) adding the micronized bedaquiline to a liquid medium to form a premix/predispersion; and
- (c) subjecting the premix to mechanical means in the presence of a grinding medium to reduce the average effective particle size.

15

Bedaquiline in micronized form is prepared using techniques known in the art. It is preferred that the average effective particle size of the bedaquiline active agent in the predispersion be less than about 100 μm as determined by sieve analysis. Where the average effective particle size of the micronized bedaquiline is greater than about

- 20 100 μm , it is preferred that the particles of the bedaquiline compound be reduced in size to less than 100 μm (for example to a size or size range as described herein).

The micronized bedaquiline can then be added to a liquid medium in which it is essentially insoluble to form a predispersion. The concentration of bedaquiline in the liquid medium (weight by weight percentage) can vary widely and depends on the selected surface modifier and other factors. Suitable concentrations of bedaquiline in compositions vary between about 0.1% to about 60%, or between about 1% to about 60%, or between about 10% to about 50%, or between about 10% to about 30%, e.g. about 10%, 20% or 30% (each % in this paragraph relating to w/v).

30

The premix can be used directly by subjecting it to mechanical means to reduce the effective average effective particle size in the dispersion to less than 2,000 nm. It is preferred that the premix be used directly when a ball mill is used for attrition. Alternatively, bedaquiline and, optionally, the surface modifier, can be dispersed in the liquid medium using suitable agitation such as, for example, a roller mill, until a homogeneous dispersion is achieved.

The mechanical means applied to reduce the effective average effective particle size of bedaquiline conveniently can take the form of a dispersion mill. Suitable dispersion mills include a ball mill, an attritor/attrition mill, a vibratory mill, a planetary mill, media mills, such as a sand mill and a bead mill. A media mill is preferred due to the 5 relatively shorter milling time required to provide the desired reduction in particle size. The beads preferably are ZrO₂ beads. For instance, for the nanoparticles, the ideal bead size is about 0.5 mm and, for the microparticles, the ideal bead size is about 2 mm.

10 The grinding media for the particle size reduction step can be selected from rigid media preferably spherical or particulate in form having an average size less than 3 mm and, more preferably, less than 1 mm (as low as 200 µm beads). Such media desirably can provide the particles of the invention with shorter processing times and impart less wear to the milling equipment. Examples of grinding media are ZrO₂ such as 95% ZrO₂ stabilized with magnesia or stabilized with yttrium, zirconium silicate, glass grinding 15 media, polymeric beads, stainless steel, titania, alumina and the like. Preferred grinding media have a density greater than 2.5 g/cm³ and include 95% ZrO₂ stabilized with magnesia and polymeric beads.

20 The attrition time can vary widely and depends primarily upon the particular mechanical means and processing conditions selected. For rolling mills, processing times of up to two days or longer may be required.

25 The particles should be reduced in size at a temperature that does not significantly degrade the bedaquiline compound. Processing temperatures of less than 30 to 40°C are ordinarily preferred. If desired, the processing equipment may be cooled with conventional cooling equipment. The method is conveniently carried out under conditions of ambient temperature and at processing pressures, which are safe and effective for the milling process.

30 The pharmaceutical compositions according to the present invention contain an aqueous carrier that preferably is pharmaceutically acceptable. Said aqueous carrier comprises sterile water optionally in admixture with other pharmaceutically acceptable ingredients. The latter comprise any ingredients for use in injectable formulations. Such ingredients are optional. These ingredients may be selected from one or more of a 35 suspending agent, a buffer, a pH adjusting agent, a preservative, an isotonizing agent, and the like ingredients. In one embodiment, said ingredients are selected from one or more of a suspending agent, a buffer, a pH adjusting agent, and optionally, a

preservative and an isotonizing agent. Particular ingredients may function as two or more of these agents simultaneously, e.g. behave like a preservative and a buffer, or behave like a buffer and an isotonizing agent.

- 5 Suitable optional buffering agents and pH adjusting agents should be used in amount sufficient to render the dispersion neutral to very slightly basic (up to pH 8.5), preferably in the pH range of 7 to 7.5. Particular buffers are the salts of weak acids. Buffering and pH adjusting agents that can be added may be selected from tartaric acid, maleic acid, glycine, sodium lactate/lactic acid, ascorbic acid, sodium citrates/citric acid, sodium acetate/acetic acid, sodium bicarbonate/carbonic acid, sodium succinate/succinic acid, sodium benzoate/benzoic acid, sodium phosphates, tris(hydroxymethyl)aminomethane, sodium bicarbonate/sodium carbonate, ammonium hydroxide, benzene sulfonic acid, benzoate sodium/acid, diethanolamine, glucono delta lactone, hydrochloric acid, hydrogen bromide, lysine, methanesulfonic acid, 10 monoethanolamine, sodium hydroxide, tromethamine, gluconic, glyceric, glutamic, glutaric, glutamic, ethylene diamine tetraacetic (EDTA), triethanolamine, including mixtures thereof. In an embodiment, the compositions of the invention do not contain a buffering agent.
- 15
- 20 Suitable optional preservatives comprise antimicrobials and anti-oxidants which can be selected from the group consisting of benzoic acid, benzyl alcohol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), chlorbutol, a gallate, a hydroxybenzoate, EDTA, phenol, chlorocresol, metacresol, benzethonium chloride, myristyl- γ -picolinium chloride, phenylmercuric acetate and thimerosal. Radical 25 scavengers include BHA, BHT, Vitamin E and ascorbyl palmitate, and mixtures thereof. Oxygen scavengers include sodium ascorbate, sodium sulfite, L-cysteine, acetylcysteine, methionine, thioglycerol, acetone sodium bisulfite, isoacorbic acid, hydroxypropyl cyclodextrin. Chelating agents include sodium citrate, sodium EDTA and malic acid. In an embodiment of the invention, the compositions of the invention 30 do not contain a perseverative.

An isotonizing agent or isotonifier may be present to ensure isotonicity of the pharmaceutical compositions of the present invention, and includes sugars such as glucose, dextrose, sucrose, fructose, trehalose, lactose; polyhydric sugar alcohols, 35 preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol. Alternatively, sodium chloride, sodium sulfate, or other appropriate inorganic salts may be used to render the solutions isotonic. These

isotonifiers can be used alone or in combination. The suspensions conveniently comprise from 0 to 10% (w/v), in particular 0 to 6% of isotonizing agent. Of interest are nonionic isotonifiers, e.g. glucose, as electrolytes may affect colloidal stability. In an embodiment of the invention, the compositions of the invention contain a 5 isotonizing agent or isotonifier, which, in a further embodiment is a nonionic isotonifier, such as a suitable sugar such as mannitol.

A desirable feature for a pharmaceutical composition of the invention relates to the ease of administration. The viscosity of the pharmaceutical compositions of the invention 10 should be sufficiently low to allow administration by injection. In particular they should be designed so that they can be taken up easily in a syringe (e.g. from a vial), injected through a fine needle (e.g. a 20 G 1½, 21 G 1½, 22 G 2 or 22 G 1¼ needle) in not too long a time span. In one embodiment the viscosity of the compositions of the invention is below about 75 mPa·s, or below 60 mPa·s. Aqueous suspensions of such 15 viscosity or lower usually meet the above-mentioned criteria.

Ideally, the aqueous suspensions according to the present invention will comprise as 20 much bedaquiline (or pharmaceutically acceptable salt thereof) as can be tolerated so as to keep the injected volume to a minimum, in particular from 3 to 70% (w/v), or from 3 to 60% (w/v), or from 3 to 40% (w/v), or from 10 to 40% (w/v), of bedaquiline (or pharmaceutically acceptable salt thereof). In one embodiment the aqueous suspensions of the invention contain about 50% - 70% (w/v) of bedaquiline (or pharmaceutically acceptable salt thereof), or about 40% - 60% (w/v) of bedaquiline (or pharmaceutically acceptable salt thereof), or about 30% - 50% (w/v) of bedaquiline (or pharmaceutically acceptable salt thereof). 25

In one embodiment, the aqueous suspensions may comprise by weight, based on the total volume of the composition:

- (a) from 10% to 70% (w/v), or from 20% to 60% (w/v), or from 20% to 50% (w/v), or 30 from 20% to 40% (w/v) of bedaquiline (or pharmaceutically acceptable salt thereof);
- (b) from 0.5% to 20 %, or from 2% to 15% or 20% (w/v), or from 5% to 15% (w/v) of a wetting agent;
- (c) from 0% to 10%, or from 0% to 5%, or from 0% to 2%, or from 0% to 1% of one 35 or more buffering agents;
- (d) from 0% to 20 %, or from 2% to 15% or 20% (w/v), or from 5% to 15% (w/v) of a isotonizing agent

- (e) from 0% to 2% (w/v) preservatives; and
- (f) water for injection q.s. ad 100%.

5 In one embodiment, the aqueous suspensions may comprise by weight, based on the total volume of the composition:

- (a) from 3% to 50% (w/v), or from 10% to 40% (w/v), or from 10% to 30% (w/v), of bedaquiline (or pharmaceutically acceptable salt thereof);
- (b) from 0.5% to 10 %, or from 0.5% to 2% (w/v) of a wetting agent;
- (c) from 0% to 10%, or from 0% to 5%, or from 0% to 2%, or from 0% to 1% of one 10 or more buffering agents;
- (d) from 0% to 10 %, or from 0% to 6% (w/v) of a isotonizing agent
- (e) from 0% to 2% (w/v) preservatives; and
- (f) water for injection q.s. ad 100%.

15 To the suspensions may optionally be added an amount of acid or base to bring the pH to a value of about pH 7. Suitable acids or bases are any of those that are physiologically acceptable, e.g. HCl, HBr, sulfuric acid, alkali metal hydroxides such as NaOH. In an embodiment, such acid or base need not be added to the compositions of the invention.

20 The administration of bedaquiline (or pharmaceutically acceptable salt thereof) as in the present invention may suffice to treat a pathogenic mycobacterial infection although in a number of cases it may be recommendable to co-administer other anti-TB drugs.

25 In certain instances, the treatment of a pathogenic mycobacterial infection may be limited to only the administration of a composition of bedaquiline (and/or its metabolite thereof) in accordance with this invention, i.e. as monotherapy without co-administration of further anti-TB drugs. This option may be recommended, for example, for certain mycobacterial infections where a low concentration of the active 30 ingredient may treat the bacteria (e.g. for latent/dormant TB or for *Mycobacterium leprae*).

35 In a further aspect the present invention relates to the use of a pharmaceutical composition comprising an effective amount of bedaquiline or a pharmaceutically acceptable salt thereof, in accordance with the present invention, for the manufacture of a medicament for maintenance therapy of a subject being infected with a pathogenic mycobacterial infection, wherein the composition is administered or is to be

administered intermittently at a time interval that is in the range of one week to one year, or one week to two years.

Thus in a further aspect, the present invention provides a method for the long term
5 treatment of a patient being infected with a pathogenic mycobacterial infection, said
method comprising
(i) the treatment of said patient with a combination of anti-TB drugs; followed by
(ii) the intermittent administration of a pharmaceutical composition comprising an
10 effective amount of bedaquiline or a pharmaceutically acceptable salt thereof, in
accordance with the present invention, wherein the composition is administered at a
time interval of at least one week.

Where, the treatment is directed towards *Mycobacterium leprae*, then again the
treatment regime might be given as monotherapy or in combination with existing drugs
15 useful for the treatment of *Mycobacterium leprae* (e.g. rifapentine). The composition of
the invention might be administered by injection once, or up to three times, e.g. as
monthly intervals. Advantages are associated with compliance, no resistance by
avoiding dapsone, no stigma by avoiding clofazimine.

20 The present invention also concerns a pharmaceutical composition as described
hereinbefore for use as a medicament in the treatment or prophylaxis of a pathogenic
mycobacterial infection.

25 In addition, the present invention concerns the use of a pharmaceutical composition as
described herein for the preparation of a medicament for the prophylaxis or treatment
of a pathogenic mycobacterial infection.

30 The present invention further concerns a method of treating a subject infected with a
pathogenic mycobacterial infection, said method comprising the administration of a
therapeutically effective amount of a pharmaceutical composition as described herein.

As used herein, the word "substantially" does not exclude "completely" e.g. a
composition which is "substantially free" from Y may be completely free from Y.
Where necessary, the word "substantially" may be omitted from the definition of the
35 invention. The term "about" in connection with a numerical value is meant to have its
usual meaning in the context of the numerical value. Where necessary the word "about"
may be replaced by the numerical value $\pm 10\%$, or $\pm 5\%$, or $\pm 2\%$, or $\pm 1\%$.

All documents cited herein are incorporated by reference in their entirety.

The following examples are intended to illustrate the present invention and should not be construed as limiting the invention thereto.

5

Example 1: preparation of micro- and nano-suspensions

The active ingredient bedaquiline may be used as such or may be converted into a pharmaceutically acceptable salt thereof, such as a fumarate salt (for example the form used in the marketed product Sirturo®). Where referred to herein, bedaquiline is used 10 in its non-salt form unless otherwise specified.

The prototype of the bedaquiline formulation is as follows:

Preparation of 200 and 100 mg/mL nano- and micro-suspensions.

15 Materials used:

Zirconium beads 0.5 mm (to aid process)
Sterile water for injection (Viaflo)
Bedaquiline (not milled/ground)
Tocopheryl PEG 1000 succinate – an excipient
20 Zirconium beads 2 mm (to aid process)
Mannitol (parenteral) – an excipient

Glass bottles and ZrO₂ beads (either 0.5 mm or 2 mm, depending on the desired nano- 25 or micro-suspensions), used as the milling media, were sterilized in an autoclave. The drug substance (quantity depending on the formulation to be prepared; see e.g.

formulation/suspension below) was put into the glass bottle as well as a solution of Tocopheryl PEG 1000 succinate in water (quantity depending on the concentration required/desired; see e.g. formulation/suspension below) for injection. ZrO₂-beads with an average particle size of 500 µm or 2 mm (depending on whether a micro- or nano- 30 suspension is required/desired) were added. The bottle was placed on a roller mill. The suspension was micronized/nanonized at 100 rpm for a period of time up to 72 hours. For instance, micronizing may be performed at 100 rpm for a period of 3 hours (or up to 3 hours) and nanonizing may be performed at 100 rpm for a period of up to 46 hours (e.g. about 40 hours). At the end of the milling process the concentrated micro- or 35 nano-suspension was removed with a syringe and filled into vials. The resulting formulations (based on the nano-suspension and micro-suspension) are described in the following tables. Determination of the concentration was done by HPLC/UV. If

needed, a dilution was made to a final concentration of 200 mg/ml of active ingredient bedaquiline. The resulting suspension was shielded from light. Other concentrations were also made and tested, including 300 mg/ml and 100 mg/ml nano- and micro-formulations.

5

Such formulations were (and will be) dosed intramuscular and subcutaneous in animals for PK study to investigate a possible long-acting effect (e.g. in treatment of leprosy). Physical stability of the suspensions will be followed up by measuring particle size after different storage conditions.

10

Certain embodiments of the formulation(s) have the following features:

- Micro-suspension by using 2 mm Zr beads
- Milling at 200 mg/mL (otherwise the concentration may be too high, e.g. with 300 mg/ml)
- Longer milling, resulting in nano-suspension
- A suitable surface modifier, for instance selected based on physical stability, e.g. in one embodiment it is TPGS, and, in another embodiment it is Tween

Examples of bedaquiline micro- and nano-suspensions

20 200 mg/ml nano- and micro-suspension referred to herein as Example 1A (nano) and Example 1B (micro)

	mg/ml
Bedaquiline	200
TPGS	50
Mannitol	50
Sterile water for injection	q.s.

25 100 mg/ml nano- and micro-suspension referred to herein as Example 1C (nano) and Example 1D (micro)

	mg/ml
Bedaquiline	100
TPGS	25
Mannitol	50
Sterile water for injection	q.s.

-30-

Particle Size Distribution (PSD) of the above formulations

Where applicable, ND = not determined

PSD for 200 mg/ml micro-suspension (Example 1B)

5

Storage temperature (°C)	Storage time	D10 (μm)	D50 (μm)	D90 (μm)
After preparation		1.316	3.283	9.623
5	3 days	1.256	2.539	5.991
	14 days	1.142	2.582	7.386
	1 month	1.157	2.423	5.850
	3 months	1.065	2.225	5.141
25	3 days	1.150	2.348	5.447
	14 days	1.073	2.308	5.824
	1 month	1.098	2.322	5.665
	3 months	1.178	2.452	5.826
40	3 days	1.110	2.227	4.913
	14 days	1.054	2.211	5.115
	1 month	1.182	2.254	4.626
	3 months	0.998	1.89	3.734

PSD for 200 mg/ml nano-suspension (Example 1A)

Storage temperature (°C)	Storage time	D10 (μm)	D50 (μm)	D90 (μm)
After preparation		0.074	0.175	1.693
5	3 days	0.076	0.185	1.920
	14 days	0.081	0.219	8.995
	1 month	0.075	0.176	1.281
	3 months	0.076	0.183	1.884
25	3 days	0.111	41.364	226.147
	14 days	ND	ND	ND
	1 month	ND	ND	ND
	3 months	ND	ND	ND
40	3 days	0.097	0.483	168.316
	14 days	0.1	0.642	240.375
	1 month	0.089	0.294	63.986
	3 months	0.088	0.274	4.279

PSD for 100 mg/ml micro-suspension (Example 1D)

Storage temperature (°C)	Storage time	D10 (μm)	D50 (μm)	D90 (μm)
After preparation		1.267	2.557	6.236
5	3 days	1.157	2.376	5.506
	14 days	0.125	0.320	0.993
	1 month	1.1	2.337	5.625
	3 months	1.048	2.236	5.269
25	3 days	0.697	1.906	4.324
	14 days	0.151	1.770	4.351
	1 month	0.171	1.797	4.253
	3 months	1.104	2.266	5.142
40	3 days	0.547	1.657	3.502
	14 days	0.203	1.709	3.881
	1 month	1.016	1.996	4.199
	3 months	1.025	1.936	3.867

5 PSD for 100 mg/ml nano-suspension (Example 1C)

Storage temperature (°C)	Storage time	D10 (μm)	D50 (μm)	D90 (μm)
After preparation		0.072	0.159	0.576
5	3 days	0.074	0.173	0.765
	14 days	0.080	0.213	7.889
	1 month	0.075	0.177	0.780
	3 months	0.074	0.172	0.919
25	3 days	0.076	0.181	0.872
	14 days	0.080	0.202	1.351
	1 month	0.080	0.203	1.673
	3 months	0.083	0.222	1.691
40	3 days	0.077	0.187	1.017
	14 days	0.082	0.226	2.893
	1 month	0.084	0.235	2.356
	3 months	0.084	0.239	2.472

Example 2: pharmacokinetic studies**Study A – pharmacokinetic profile in mice**

A single dose of bedaquiline was administered to the mouse orally and the plasma kinetics of bedaquiline itself (also referred to as “TMC207”) and its main metabolite,

5 N-monodesmethyl (also referred to as “M2”), were measured over a period of 168 hours. M2 seems to be an active metabolite and its formation, upon administration of bedaquiline (TMC207), is seen in at least the following species: mouse, rat/dog and human (its formation being the most in mouse and least in humans).

10 The results are as described in Figure 1: “Plasma kinetics of TMC207 and M2 in mouse, after a single dose of 30 mg/kg”

It could be seen that:

- TMC207 and M2 plasma kinetics are slow; the formation of M2 is also slow
 - 15 - M2 plasma exposure (AUC) is greater than the TMC207 exposure
 - M2 lung concentrations is a lot greater than TMC207 lung concentrations
 - After a period of 168 hours, the concentration of TMC207 in the plasma is about 0.01 µg/ml and of M2 is about 0.1 µg/ml
- 20 As described in Example 1, the 200 mg/ml and 100 mg/ml micro- and nano-suspensions (Examples 1A, 1B, 1C and 1D) were tested on mice, where the mice either received:
 - a dose of 80 mg/kg (in which case the 100 mg/ml suspensions were used, i.e. Example 1C and 1D) or 160 mg/kg (in which case the 200 mg/ml suspensions
 - 25 were used, i.e. Example 1A and 1B)
 - were dosed intramuscularly (IM) or subcutaneously (SM)

30 Each of the formulations 1A, 1B, 1C and 1D were tested in a suspension API assay before administering into the mice, and it was determined that the API was in the range of 75-142% (an unusually broad range). However, in the mice, the plasma levels of bedaquiline and its metabolite could still be measured and assessed after administering such formulations.

Phase 1 of the Results – up to 672 hours

Figure 2 “Plasma kinetics of TMC207 in mouse when administered IM or SC with 200 mg/ml formulations (specifically formulations of Examples 1A and 1B, i.e. the nano- and micro-suspension, respectively) at a dose of 160 mg/kg” (TMC207 is referred to the in the Figure as “UD”)

Figure 3 “Plasma kinetics of M2 in mouse when administered IM or SC with 200 mg/ml formulations (specifically formulations of Examples 1A and 1B, i.e. the nano- and micro-suspension, respectively) at a dose of 160 mg/kg” (M2 is referred to in the Figure as “met”)

Generally, it can be seen that:

- for the TMC207 concentrations, the C_{max} ranges from between about 3000 ng/ml (the highest for the micro-suspension dosed IM) to about 100 ng/ml (the lowest being for the micro-suspension dosed SC)
- at 672 hours, there was still a measureable concentration of TMC207 ranging from about 200 ng/ml (the highest for the micro-suspension dosed IM) to about 50 ng/ml (for lowest for the micro-suspension dosed SC)
- for the M2 concentrations, the C_{max} ranges from between about 3000 ng/ml (the highest for the micro-suspension dosed IM) to about 300 ng/ml (the lowest for the micro-suspension dosed SC)
- at 672 hours, there was still a measureable concentration of M2 ranging from about 1000 ng/ml (the highest for the micro-suspension dosed IM) to about 200 ng/ml (the lowest for the micro-suspension dosed SC)

Figure 4 “Plasma kinetics of TMC207 in mouse when administered IM or SC with 100 mg/ml formulations (specifically formulations of Examples 1C and 1D, i.e. the nano- and micro-suspension, respectively) at a dose of 80 mg/kg” (TMC207 is referred to the in the Figure as “UD”)

Figure 5 “Plasma kinetics of M2 in mouse when administered IM or SC with 100 mg/ml formulations (specifically formulations of Examples 1C and 1D, i.e. the nano- and micro-suspension, respectively) at a dose of 80 mg/kg” (M2 is referred to in the Figure as “met”)

Generally, it can be seen that:

- for the TMC207 concentrations, the C_{max} ranges from between about 2000 ng/ml (the highest for the nano-suspension dosed IM) to about 400 ng/ml (the lowest being for the nano- and micro-suspension dosed SC)
- 5 - at 672 hours, there was still a measurable concentration of TMC207 ranging from about 100 ng/ml (the highest for the micro-suspension dosed IM) to about 30 ng/ml (for lowest for the micro-suspension dosed SC)
- for the M2 concentrations, the C_{max} ranges from between about 2000 ng/ml (the highest for the nano-suspension dosed IM) to about 300 ng/ml (the lowest for 10 the micro-suspension dosed SC)
- at 672 hours, there was still a measurable concentration of M2 ranging from about 500 ng/ml (the highest for the micro-suspension dosed IM) to about 100 ng/ml (the lowest for the micro-suspension dosed SC)

15 Phase 2 of the Results – up to 2184 hours

The mice of these studies were further monitored up to 2184 hours, giving the following results:

- for Formulation 1A, i.e. the nano-suspension of 200 mg/ml concentration, and 20 dosed SC at 160 mg/kg (StDev = standard deviation) and IM at 160 mg/kg

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 160 mg/kg				IM at 160 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
1	493	305	59.3	49.6	1517	710	171	71
4	676	384	284	188	1588	662	708	332
7	728	269	484	312	1408	519	1063	456
24	726	53	956	289	1022	299	2071	828
168	239	28	1240	475	219	63	1399	557
336	138	66	759	282	99.0	33.2	597	301
504	122	53	503	178	66.1	26.1	418	209
672	109	22	383	136	79.0	34.8	405	211
840	100.8	42.5	196.0	76.5	69.6	58.5	119.2	60.3
1176	70.3	31.0	117.8	50.0	34.7	13.8	65.7	30.9
1512	58.5	20.1	91.2	42.5	23.4	8.4	40.3	18.1
1848	40.6	16.6	86.3	41.7	17.4	7.3	29.7	15.8
2184	35.2	21.4	65.1	36.6	14.5	6.7	27.3	13.2

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 160 mg/kg				IM at 160 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
T max (h)	4-24		168		1-4		24	
Cmax (ng/mL)	862	202	1240	475	1723	764	2071	828
t _{1/2} (h)	910	442	1024	573	964	572	794	403
AUClast (ng*h/mL)	247783	54315	702286	173934	207109	69394	696089	302612
AUC _{inf} (ng*h/mL)	301991	107533	815741	282889	231176	89366	728091	318248

- for Formulation 1C, i.e. the nano-suspension of 100 mg/ml concentration, and dosed SC at 80 mg/kg and IM at 80 mg/kg

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 80 mg/kg				IM at 80 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
1	261	66	22.0	3.5	1515	568	177	51
4	538	288	222	88	1572	470	684	239
7	480	281	342	108	1458	314	1049	256
24	205	109	545	185	1114	299	2186	834
168	65.6	30.9	298	130	186	46	1393	744
336	42.5	21.5	192	122	89.0	23.1	609	342
504	46.3	38.3	178	165	54.9	15.0	400	198
672	41.9	36.9	145	136	57.2	27.3	285	121
840	33.9	20.3	70.5	59.2	52.6	40.5	107	54
1176	25.4	15.9	47.2	37.5	28.2	17.8	50.4	29.9
1512	22.2	12.5	43.8	31.7	17.0	11.0	33.8	21.8
1848	14.1	7.3	28.8	18.8	12.6	9.1	23.2	17.4
2184	12.9	6.8	24.1	14.3	7.28		18.3	14.2
T max (h)	4-7		24		1-7		24	
Cmax (ng/mL)	557	265	545	185	1806	473	2186	834
t _{1/2} (h)	1051	390	796	147	581	159	650	122

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 80 mg/kg				IM at 80 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
AUClast (ng*h/mL)	84121	43933	238239	136814	186882	61016	669899	325833
AUCinf (ng*h/mL)	102985	47867	264292	149139	196358	68907	688601	344341

- for Formulation 1B, i.e. the micro-suspension of 200 mg/ml concentration, and dosed SC at 160 mg/kg (StDev = standard deviation) and IM at 160 mg/kg

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 160 mg/kg				IM at 160 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
1	71.1	15.1	6.53	2.02	1737	1752	206	247
4	101	7	37.5	7.1	2258	1229	908	734
7	102	12	55.3	17.7	1764	1103	1474	795
24	130	19	186	36	1306	407	2926	1143
168	78.7	5.3	276	61	391	137	2643	1087
336	53.8	3.5	226	45	293	131	1693	798
504	51.1	8.3	196	37	222	101	1526	773
672	67.4	12.8	266	52	231	115	1202	680
840	65.7	28.9	114.3	36.6	163.5	74.1	387.8	198.0
1176	55.1	36.2	104.6	51.3	121.9	48.7	255.0	137.4
1512	38.2	13.6	95.6	34.4	94.0	60.7	165.2	91.2
1848	36.9	11.0	66.7	22.8	65.6	23.3	146.4	80.8
2184	30.7	10.4	60.9	21.9	51.5	26.1	112	62
T max (h)	24		168-672		1-4		24-168	
Cmax (ng/mL)	130	19	309	30	2364	1447	3002	1139
t1/2 (h)	1545	253	1294	383	719	70	848	273
AUClast (ng*h/mL)	117569	30034	300334	63219	447361	174979	1689422	755169
AUCinf (ng*h/mL)	188153	60663	412456	107222	500850	201928	1823672	836740

- for Formulation 1D, i.e. the micro-suspension of 100 mg/ml concentration, and dosed SC at 80 mg/kg (StDev = standard deviation) and IM at 80 mg/kg

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 80 mg/kg				IM at 80 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
1	133	114	6.70		463	186	29.7	12.1
4	415	533	130	175	873	221	264	41
7	350	412	232	310	850	200	459	60
24	162	47	360	364	709	228	1101	341
168	53.2	18.3	226	112	209	44	1050	405
336	28.7	6.8	107	35	112	12	547	150
504	28.2	0.8	109	27	71.8	17.5	398	121
672	28.6	5.8	105	33	87.0	17.0	444	127
840	25.9	6.8	56.3	22.9	70.9	19.6	130	36
1176	25.3	4.5	42.9	15.8	41.5	8.4	91.2	27.4
1512	20.2	6.9	42.1	16.4	31.1	9.5	68.8	26.8
1848	19.6	8.0	31.5	14.7	24.0	7.0	43.7	15.2
2184	15.2	5.4	32.7	16.1	26.3	14.2	42.2	16.7
T max (h)	4-24		24-168		4-7		24-168	
Cmax (ng/mL)	433	517	383	348	925	192	1139	366
t1/2 (h)	1423	535	1082	437	916	337	734	322
AUClast (ng*h/mL)	69275	7996	175236	48413	192325	36480	586546	165428
AUCinf (ng*h/mL)	103115	29066	226669	50867	225966	51489	632846	193499

5 Study B – pharmacokinetic profile in rats and beagle dogs

Formulations of concentrations 200 mg/mL were used in this study, both the nano-suspension (Formulation 1A) and the micro-suspension (Formulation 1B), as depicted above in Example 1 (i.e. using, in addition to the 200 mg/ml concentration of micro- and nano-particles (of the active bedaquiline), TPGS (4:1 bedaquiline : TPGS) and

10 50 mg/ml Mannitol in WFI (water for injection)).

These studies demonstrate that formulations described in Example 1 (specifically the nano- and micro-formulations 1A and 1B) results in stable plasma levels over a prolonged period of time in male rats and male beagle dogs, when administered subcutaneously (SC) and intramuscularly (IM).

5

Male Rats

The first experiment was performed on male rats, where each relevant 200 mg/ml nano-suspension and micro-suspension referred to above were administered subcutaneously (SC) and intramuscularly (IM) at a concentration of 40 mg/kg (0.2 mL/kg). An interim

10 analysis was performed at 3 months and the results were followed-up at 6 months.

Twelve rats were used in the study. Six rats were dosed intramuscularly (IM), three of those rats with the 200 mg/ml nano-suspension (see Example 1, Formulation 1A above) and the other three with the 200 mg/ml micro-suspension (see Example 1, Formulation 1B above). Six rats were dosed subcutaneously (SC), three of those rats with the

15 200 mg/ml nano-suspension (see Formulation 1A above) and the other three with the 200 mg/ml micro-suspension (see Formulation 1B above).

Phase 1 of the Results – up to 2200 hours

Figure 6 “Plasma kinetics of TMC207 in male rats when administered IM or SC with

20 200 mg/ml micro-formulation (see Example 1, Formulation 1B i.e. the micro-suspension) at a dose of 40 mg/kg” and “Plasma kinetics of TMC207 in male rats when administered IM or SC with 200 mg/ml nano-formulation (see Example 1, Formulation 1A, i.e. the nano-suspension) at a dose of 40 mg/kg”

25 The following parameters were calculated for TMC207 (see Figure 6):

	Microsuspension (Form 1B) SC	Microsuspension (Form 1B) IM	Nanosuspension (Form 1A) SC	Nanosuspension (Form 1A) IM
n	3	3	3	3
C _{max} (ng/ml)	68.1 ± 17.6	215 ± 66.7	337 ± 57.0	505 ± 96.6
T _{max} ^a (h)	24 (24.00 - 24.00)	18 (7.00 - 24.00)	24 (24.00 - 24.00)	16 (1.00 - 24.00)
T _{last} ^a = around 3 mths (h)	2184 (2184 - 2184)	2184 (2184 - 2184)	2184 (2184 - 2184)	2184 (2184 - 2184)
AUC _{0-2184h} (3 mths) (ng.h/ml)	34700 ± 1770	91500 ± 13200	75400 ± 5070	77900 ± 8930

where applicable mean values are given (with min → max in parentheses)

Generally, it can be seen that:

- after microsuspension administration, higher (2.6 fold) AUC after IM versus SC. After nanosuspension administration, similar AUC after SC or IM
- in terms of bioavailability (comparison with IV 5 mg/kg), for the lowest (microsuspension SC) = 56%, for the 3 other > 100 %
- M2, which is not specified on the graphs in Figure 6, has the same profiles as TMC207 except that t_{max} is later, AUC of M2 is 1.5 to 2 fold lower than TMC207; in general this ratio is comparable to PO route

A comparison was also performed with oral (PO) administration in rats, which can also be considered a 13 week toxicity study, where the following result was observed:

- The exposures (C_{max} and AUC) at 3 months after single IM or SC for both formulations are much lower than the total exposure after PO administration at the top dose of 13 week study : IM/SC 34500-91500 ng.h/mL versus PO a total exposure = 2 385 383 ng.h/mL during the same period of time (3 months)
- see above regarding M2

20 Male Beagle Dogs

The second experiment was performed on male beagle dogs, where each relevant 200 mg/ml nano-suspension and micro-suspension referred to above were administered subcutaneously (SC) and intramuscularly (IM) at a concentration of 40 mg/kg (0.2 mL/kg). An interim analysis was performed at 3 months and the results were followed-up at 6 months. Twelve (12) healthy male beagle dogs with body weights ranging from 8 to 16 kg at the start of the study, were used. Each dog was identified by an ear tattoo number. Six dogs were dosed intramuscularly (IM) in the left and right m. biceps femoris, three of those dogs with the 200 mg/ml nano-suspension (see Example 1, Formulation 1A above) and the other three with the 200 mg/ml micro-suspension (see Example 1, Formulation 1B). Six dogs were dosed subcutaneously (SC) in the left and right thoracal region, three of those dogs with the 200 mg/ml nano-suspension (see Formulation 1A above) and the other three with the 200 mg/ml micro-suspension (see Formulation 1B above).

35 Blood samples of 3 ml were taken from the left jugular vein from all dogs on day 0 at 0 h (predose), 20 min, 1 h, 3 h, 8 h and 24 h post-dose and further on days 2, 3, 6, 8, 10, 13, 16, 20, 23, 27, 29, 36, 43, 50, 57, 64, 71, 78, 85 and 92 at approximately 8 AM.

-40-

5 Blood samples were placed on EDTA, EDTA Vacutte Greiner, Cat. No. 454086, Greiner Labortechnik N.V.). Within 2 h of blood sampling, samples were centrifuged at room temperature at about 1900x g for 10 minutes to allow plasma separation. Plasma was immediately transferred into a second tube and stored in the freezer within 2 hours after the start of centrifugation. Plasma samples were analysed individually for TMC207, and for its metabolite M2, by means of a validated LC-MS/MS-method.

10 Figure 7 “Plasma kinetics of TMC207 in male beagle dogs when administered IM or SC with 200 mg/ml micro-formulation (see Example 1, Formulation 1B) at a dose of 40 mg/kg” and “Plasma kinetics of TMC207 in male beagle dogs when administered IM or SC with 200 mg/ml nano-formulation (see Example 1, Formulation 1A) at a dose of 40 mg/kg”

15 The following parameters were calculated for TMC207 (see Figure 7):

	Microsuspension (Form 1B) SC	Microsuspension (Form 1B) IM	Nanosuspension (Form 1A) SC	Nanosuspension (Form 1B) IM
n	3	3	3	3
C _{max} (ng/ml)	219 ± 237	822 ± 211	692 ± 217	4150 ± 1290
T _{max} ^a (h)	620 (168.00 - 840.00)	3.0 (1.00 - 7.00)	168 (168.00 - 168.00)	2.0 (1.00 - 4.00)
T _{last} ^a = around 3 mths (h)	2184 (2184 - 2184)	2184 (2184 - 2184)	2184 (2184 - 2184)	2184 (2184 - 2184)
AUC _{last} (ng.h/ml)	268000 ± 250000	519000 ± 64300	483000 ± 65300	549000 ± 26200

where applicable mean values are given (with min → max in parentheses)

Generally, it can be seen that:

- 20
- after microsuspension administration, higher (2 fold) AUC after IM versus SC
 - after nanosuspension administration, similar AUC after SC or IM
 - in terms of C_{max} higher after IM versus SC for both formulation
 - in terms of bioavailability (comparison with IV 1 mg/kg) > 100 %
 - M2 has the same profiles as TMC207 except that t_{max} is later, AUC is 3 to 4 fold lower than TMC207; in general this ratio is comparable to PO route

25

A comparison was also performed with oral (PO) administration in rats, which can be considered as a 13 week toxicity study, where the following result was observed:

- The highest C_{max} after IM nanosuspension similar to the C_{max} after PO at 18 mg/kg; in terms of exposure much higher total exposure after PO versus after IM/SC: IM/SC 268000-549000 ng.h/mL versus PO a total exposure = 13 988 520 ng.h/mL for the same period
- See above for M2

Based on the 3-month interim results, we have the following conclusions:

- 10 After IM/SC nanosuspension/microsuspension:
- In rats, AUC: IM micro > SC nano ≈ IM nano (more rapid decline) > SC micro
 - In dogs, AUC: IM micro > SC nano ≈ IM nano > SC micro (similar decline for the 4 profiles)

At 40 mg/kg after IM/SC nanosuspension/microsuspension, C_{max} and AUC of

- 15 TMC207/M2 are covered by oral tox studies in both species except for the C_{max} of TMC207 in dogs after IM nanosuspension which is similar between PO and IM

Phase 2 of the Results – up to 4400 hours

In all cases the plasma concentration of BDQ or M2 is calculated as the mean of the

- 20 three animals (rats or dogs) in the relevant study.

Study in rats: for Formulation 1B, i.e. the micro-suspension of 200 mg/ml concentration, and dosed SC at 40 mg/kg (StDev = standard deviation) and IM at 40 mg/kg

25

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 40 mg/kg				IM at 40 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
1	22.1	5.36	0.589	NC	139	33.2	5.11	2.24
4	36.9	7.42	6.62	1.69	172	47.2	18.8	5.98
7	40.7	6.27	8.59	1.46	185	24.2	28.7	7.57
24	68.1	17.6	24.0	1.14	212	70.6	77.3	23.5
168	16.5	4.84	9.03	1.81	98.0	19.1	91.5	33.1
336	18.1	3.30	9.28	2.10	69.7	10.2	54.9	16.8
504	22.8	3.96	9.68	2.85	52.2	4.05	37.9	16.5
672	14.7	0.964	7.32	1.34	42.6	6.85	29.5	14.8
840	15.1	1.74	7.40	2.46	33.6	6.39	22.3	10.6

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 40 mg/kg				IM at 40 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
1008	14.7	3.47	6.82	2.06	28.5	6.24	20.2	11.2
1176	13.2	2.99	5.96	1.76	24.1	7.04	16.6	9.37
1344	12.4	2.34	6.10	1.79	20.7	3.07	14.1	8.88
1512	12.0	0.917	5.81	1.81	19.7	5.98	13.4	7.16
1680	12.3	1.95	5.42	2.01	18.4	3.30	11.5	5.77
1848	10.6	0.83	5.18	1.51	14.3	1.35	11.4	6.39
2016	9.83	2.06	4.30	2.03	14.9	1.75	9.86	3.75
2184	10.2	2.42	4.55	1.36	12.6	0.755	8.87	3.37
2520	9.45	2.16	5.54	1.82	11.6	2.06	9.27	3.53
2856	8.26	0.737	4.78	1.61	10.5	2.65	7.49	3.02
3192	6.82	1.38	4.04	1.02	8.67	2.71	6.28	2.52
3528	6.83	2.27	4.02	1.05	6.92	2.09	5.68	2.79
3864	6.69	0.794	3.95	0.866	5.90	2.21	5.00	2.53
4200	6.41	1.72	3.49	0.987	4.41	2.04	3.74	2.03
≈ CV%	8 – 29		NC – 47		6 – 46		26 – 63	
T max (h)	24		24		18		120	83
Cmax (ng/mL)	68.1	17.6	24.0	1.14	215	66.7	94.2	33.3
T last (h)	4200		4200		4200		4200	
AUClast (ng*h/mL)	50200	4240	24800	5520	109000	12300	75200	28700
AUC ₀₋₂₈₅₆ (ng*h/mL)	41000	2880	19300	4150	99200	13200	67600	26100
AUC _{inf} (ng*h/mL)	NC		NC		121000	11400	85500	28800

Study in Rats: for Formulation 1A, i.e. the nano-suspension of 200 mg/ml concentration, and dosed SC at 40 mg/kg (StDev = standard deviation) and IM at 40 mg/kg (in this case, small sample size applied to calculation of summary variable)

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 40 mg/kg				IM at 40 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
1	42.1	11.4	BOL^a	NC	329	256	12.0	5.77
4	81.5	17.0	11.7	3.50	365	176	39.5	16.7
7	98.7	25.2	20.3	4.15	385	124	68.6	30.4
24	337	57.0	127	20.8	436	41.2	217	36.3
168	92.4	33.6	100	17.7	94.9	25.1	89.9	21.8
336	62.7	5.61	62.9	25.3	53.0	13.0	48.6	21.2
504	42.1	6.21	45.8	30.7	36.2	7.49	26.6	12.0
672	28.4	1.04	32.4	22.5	22.4	3.35	15.8	5.31
840	20.8	3.67	21.1	13.4	25.9	2.48	11.1	2.50
1008	16.5	4.56	16.2	12.0	12.0	1.55	8.13	1.82
1176	12.7	4.58	12.7	10.0	9.05	1.23	5.74	1.07
1344	12.0	7.04	10.1	9.35	7.33	0.739	4.20	1.18
1512	7.02	2.77	7.61	6.32	4.69	0.384	3.05	0.640
1680	6.05	2.79	6.02	NC	4.57	0.378	2.63	0.242
1848	4.95	2.56	5.35	5.22	4.05	0.192	1.56	NC
2016	4.36	2.12	4.08	NC	3.21	0.646	1.92	0.246
2184	3.77	1.94	3.49	NC	2.50	0.0231	1.80	0.102
2520	2.72	1.67	2.97	2.62	2.27	0.437	1.45	0.121
2856	2.51	0.880	2.50	2.16	1.56	0.335	0.926	0.0759
3192	1.51	0.892	2.14	NC	1.26	0.275	0.841	0.0826
3528	1.50	NC	1.28	NC	1.37	NC	BOL^a	NC
3864	0.887	NC	BOL^a	NC	BOL^a	NC	BOL^a	NC
4200	0.753	NC	BOL^a	NC	BOL^a	NC	BOL^a	NC
≈ CV%	NC – 61		NC – 90		1 – 78		NC – 48	
T max (h)	24		24		16		24	
Cmax (ng/mL)	337	57.0	127	20.8	505	96.6	217	36.3
T last (h)	3900	580	3500	670	3500	340	3300	190

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 40 mg/kg				IM at 40 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
AUClast (ng*h/mL)	79100	3100	67200	33600	80400	8260	53400	10700
AUC ₀₋₂₈₅₆ (ng*h/mL)	77300	4240	65400	31200	79400	8800	53000	10700
AUC _{inf} (ng*h/mL)	80100	2890	68600	34500	81200	8230	54000	10700

NC = not calculated

BOL^a = below limit of quantification (0.75 ng/mL or 1.5 ng/mL)

Study in Dogs: for Formulation 1B, i.e. the micro-suspension of 200 mg/ml

5 concentration, and dosed SC at 40 mg/kg (StDev = standard deviation) and IM at 40 mg/kg.

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 40 mg/kg				IM at 40 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
1	1.55	0.0794	BOL^a	NC	765	136	BOL^a	NC
4	5.43	1.48	BOL^a	NC	703	292	14.9	5.87
7	8.80	2.48	BOL^a	NC	735	274	21.2	8.72
24	21.9	13.0	BOL^a	NC	349	28.3	27.7	9.76
168	192	261	32.9	40.1	351	65.6	69.8	11.6
336	160	173	47.1	46.9	355	30.2	94.2	7.02
504	149	151	50.4	51.5	338	30.0	93.8	13.2
672	123	109	46.2	43.1	284	37.8	90.6	16.9
840	161	138	53.1	48.2	315	30.1	96.2	3.24
1008	125	104	50.1	40.1	227	25.2	80.7	4.11
1176	116	96.4	42.8	34.9	187	45.1	60.8	13.0
1344	110	96.2	40.4	31.9	172	38.7	52.8	11.1
1512	108	93.5	41.0	35.7	171	34.4	62.1	14.2
1680	136	107	39.7	31.9	183	37.6	51.8	6.85
1848	93.0	75.4	37.4	30.4	135	43.4	46.9	9.40
2016	89.5	71.4	35.9	26.0	121	31.1	41.2	7.86
2184	82.0	59.8	28.6	23.4	108	28.4	37.1	9.31
2520	83.1	58.8	29.8	24.3	88.0	28.4	29.2	7.60

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 40 mg/kg				IM at 40 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
2856	75.3	53.5	28.8	23.2	74.3	23.5	26.4	5.30
3192	60.3	36.1	23.8	15.4	58.7	17.6	22.1	5.17
3528	59.1	34.3	20.3	13.4	54.0	17.2	18.9	6.60
3864	52.8	26.0	20.1	11.0	45.4	15.8	16.4	5.17
4200	51.7	30.2	20.4	13.2	40.9	14.6	15.6	4.63
≈ CV%	5 – 136		NC – 122		8 – 42		3 – 41	
T max (h)	620	390	780	260	3.0		620	260
Cmax (ng/mL)	219	237	55.3	47.7	822	211	103	6.58
T last (h)	4200		4200		4200		4200	
AUClast (ng*h/mL)	402000	335000	138000	114000	652000	105000	193000	27900
AUCinf (ng*h/mL)	NC		NC	NC	690000	NC	NC	NC

NC = not calculated

BOL^a = below limit of quantification (3.75 ng/mL)

Study in Dogs: for Formulation 1A, i.e. the nano-suspension of 200 mg/ml

5 concentration, and dosed SC at 40 mg/kg (StDev = standard deviation) and IM at 40 mg/kg (in this case, small sample size applied to calculation of summary variable)

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 40 mg/kg				IM at 40 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
1	274	466	BOL^a	NC	4000	1510	11.1	1.35
4	194	197	BOL^a	NC	3570	620	41.7	7.25
7	157	134	4.94	NC	2690	842	51.5	10.6
24	167	52.6	8.68	6.84	742	82.3	62.6	17.2
168	692	217	127	54.6	568	142	108	27.1
336	386	55.4	132	29.0	412	19.2	112	24.4
504	318	76.8	110	7.77	321	13.1	98.4	21.0
672	244	28.4	93.8	14.9	240	29.6	84.1	25.0
840	255	29.7	93.0	5.84	254	12.7	89.4	24.5

Time (h)	Plasma concentration of bedaquiline (BDQ) or its metabolite (M2)							
	SC at 40 mg/kg				IM at 40 mg/kg			
	BDQ	StDev	M2	StDev	BDQ	StDev	M2	StDev
1008	197	40.6	74.8	2.20	172	23.4	63.7	16.2
1176	158	21.4	59.5	4.92	149	10.0	58.7	13.0
1344	133	19.5	47.3	2.10	139	13.2	47.1	12.8
1512	124	25.4	46.4	5.82	120	8.62	41.6	10.6
1680	136	24.0	43.6	3.40	126	17.0	44.5	11.7
1848	89.6	23.8	33.8	3.53	95.2	2.14	32.7	4.60
2016	84.5	18.8	31.6	3.04	89.9	16.7	31.7	7.72
2184	80.5	25.4	27.9	3.52	78.4	5.66	24.5	6.07
2520	59.7	14.8	21.1	2.04	57.4	4.47	19.4	3.07
2856	53.9	18.0	19.6	4.25	54.8	3.04	18.7	2.77
3192	45.2	16.7	16.4	4.19	42.9	4.32	14.5	2.80
3528	40.0	12.3	14.9	3.55	36.1	1.40	12.4	2.06
3864	34.5	13.1	12.8	3.20	32.3	2.42	11.5	1.82
4200	31.1	14.1	12.1	4.02	25.4	1.37	9.49	1.42
≈ CV%	12 – 170		NC – 79		2 – 38		12 – 30	
T max (h)	168		280	97	3	2.0	280	97
Cmax (ng/mL)	692	217	140	42.8	4150	1290	121	21.7
T last (h)	4200		4200		4200		4200	
AUClast (ng*h/mL)	580000	82500	186000	8740	641000	27700	174000	32900
AUCinf (ng*h/mL)	NC	NC	215000	NC	677000	24800	193000	32200

NC = not calculated

BOL^a = below limit of quantification (0.75 ng/mL)

Example 3

5 Evaluation of an injectable, long-acting bedaquiline formulation in the paucibacillary mouse model of latent tuberculosis infection

The objective of this study was to use the paucibacillary mouse model of latent tuberculosis infection (LTBI) to compare the bactericidal activity of a long-acting bedaquiline (B_{LA}) formulation administered every 4 weeks for a total of 1, 2, or 3 doses

10 to the activity of daily (5 days per week) oral dosing of B at the standard 25 mg/kg dose

or lower doses matching to total drug doses administered as B_{LA}. The original study scheme is presented in **Table 1**. The B_{LA} used for this study is that described above in Example 1B, i.e. the microsuspension at a concentration of 200 mg/ml). The primary outcome was the decline in *Mycobacterium tuberculosis* lung CFU counts during treatment.

Table 1. Original study scheme to evaluate the bactericidal activity of B_{LA} in a mouse model of paucibacillary LTBI.

LTBI treatment regimen*	Number of mice sacrificed for lung CFU counts at the following time points:						Total mice	Total dose B over 12 weeks (mg/kg)		
	BCG immunization	M.tb. challenge	Treatment initiation	During treatment						
	Week -12	Week -6	Day 0	Week 4	Week 8	Week 12				
Untreated	5	5	5	5	5	5	30	na		
R ₁₀ (5/7)				5	5	5	15	na		
P ₁₅ H ₅₀ (1/7)				5	5	5	15	na		
B ₂₅ (5/7)				5	5	5	15	1500		
B ₈ (5/7)				5	5	5	15	480		
B _{5.33} (5/7)				5	5	5	15	320		
B _{2.67} (5/7)				5	5	5	15	160		
B _{LA-160} (1/28) x 3						5	5	480		
B _{LA-160} (1/28) x 2					5	5	10	320		
B _{LA-160} (1/28) x 1				5	5	5	15	160		
Total mice	5	5	5	40	45	50	150			

10

*R, rifampin; P, rifapentine; H, isoniazid; B, bedaquiline; B_{LA}, long-acting bedaquiline formulation. All drug doses in mg/kg indicated by subscript. Fractions in parentheses indicate dosing frequency, in days. B_{LA} is administered by intramuscular injection; all other drugs are administered by gavage. na, not applicable.

15

Justification of the regimens

- Untreated mice were used to determine the level and stability of the paucibacillary infection.
- R₁₀ (5/7) is an alternative regimen for treatment of LTBI in the US and Canada, administered for 4 months. It was used here as a control to qualify the model.

20

- P₁₅H₅₀ (1/7) is an alternative regimen for treatment of LTBI in the US, administered once weekly for 3 months (12 doses). It proved at least as efficacious as 9 months of isoniazid. It is the most intermittent of currently recommended regimens and serves as a second control.
- 5 ○ B₂₅ (5/7) is daily B at the human equivalent dose previously studied in the paucibacillary model. It provides a total dose of 500 mg/kg every 28 days.
- B₈ (5/7) is daily B at a dose that is reduced to provide the same total dose (480 mg/kg) as the B_{LA} formulation dose (*i.e.*, 160 mg/kg) administered every 28 days × 3 doses.
- 10 ○ B_{5.33} (5/7) is daily B at a dose that is reduced to provide the same total dose (320 mg/kg) as the B_{LA} formulation dose (*i.e.*, 160 mg/kg) administered every 28 days × 2 doses.
- B_{2.67} (5/7) is daily B at a dose that is reduced to provide the same total dose (160 mg/kg) as the B_{LA} formulation dose (*i.e.*, 160 mg/kg) administered once.
- 15 ○ B_{LA-160} (1/28) × 3 is the B_{LA} formulation administered as 160 mg/kg every 28 days for a total of 3 doses. Thus, the total B dose will match that of the B₈ (5/7) group at each 28-day interval.
- B_{LA-160} (1/28) × 2 is the B_{LA} formulation administered as 160 mg/kg every 28 days for a total of 2 doses, beginning on Day 0. Thus, the total B dose administered by
- 20 Week 12 (320 mg/kg) will be the same as that of the B_{5.33} (5/7) group.
- B_{LA-160} (1/28) × 1 is the B_{LA} formulation administered as 160 mg/kg just once on Day 0. Thus, the total B dose administered by Week 12 (160 mg/kg) will be the same as that in the B_{2.67} (5/7) group.

25 FINAL RESULTS

All CFU count data are finalized and presented below in **Table 2**. Due to delays in finalizing institutional agreements and obtaining the B_{LA} supply, treatment was not initiated until approximately 13 weeks after the *M. tuberculosis* challenge infection, and the time line in **Table 2** has been adjusted accordingly. For comparison between 30 different treatment groups, statistical significance was assessed using one-way ANOVA adjusted with Bonferroni's multiple comparisons test.

Table 2. Final *M. tuberculosis* lung CFU count data.

LTBI treatment regimen*	Mean (SD) \log_{10} <i>M. tuberculosis</i> CFU/lung at the following time points:						Total dose B over 12 weeks (mg/kg)	
	BCG immunization	<i>M.tb.</i> challenge	Treatment initiation	During treatment				
	Week -19	Week -13	Day 0	Week 4	Week 8	Week 12		
Untreated	na	2.11 (0.09)	4.75 (0.27)	4.71 (0.48)	4.60 (0.27)	4.94 (0.29)	na	
R ₁₀ (5/7)				3.39 (0.46)	2.74 (0.62)	1.27 (0.85)	na	
P ₁₅ H ₅₀ (1/7)				2.67 (0.25)	0.79 (0.80)	0.28 (0.41)	na	
B ₂₅ (5/7)				3.01 (0.45)	0.82 (0.49)	0.07 (0.09)	1500	
B ₈ (5/7)				3.30 (0.12)	2.42 (0.26)	0.69 (0.43)	480	
B _{5.33} (5/7)				3.83 (0.25)	3.15 (0.47)	1.98 (0.17)	320	
B _{2.67} (5/7)				3.96 (0.35)	3.52 (0.38)	3.16 (0.24)	160	
B _{LA-160} (1/28) x 3						1.23 (0.16)	480	
B _{LA-160} (1/28) x 2					2.31 (0.40)	1.63 (0.40)	320	
B _{LA-160} (1/28) x 1				3.55 (0.32)	3.31 (0.38)	1.83 (0.34)	160	

*R, rifampin; P, rifapentine; H, isoniazid; B, bedaquiline, B_{LA}, long-acting bedaquiline formulation. All drug doses in mg/kg indicated by subscript. Fractions in parentheses indicate dosing frequency, in days. SD, standard deviation. na, not applicable.

BCG immunization. One-hundred fifty female BALB/c mice were infected by aerosol with *M. bovis* rBCG30. A culture suspension with an OD₆₀₀ of 1.03 was diluted 10-fold and then used for aerosol infection. The concentration of the bacterial suspension was 6.88 \log_{10} CFU/mL, which resulted in a mean implantation of 3.05 (SD 0.10) \log_{10} CFU/lung. Six weeks later, at the time of the *M. tuberculosis* challenge infection, the mean BCG burden in the mouse lungs was 4.95 (SD 0.11) \log_{10} CFU. By Day 0, the BCG burden had decreased and stabilized at 3.27 (SD 0.45) \log_{10} CFU/lung, with similar lung burdens observed in the untreated mice at Weeks 4, 8, and 12. Thus, a low-level, stable BCG infection was established in the lungs of these mice as expected.

***M. tuberculosis* challenge.** Six weeks after BCG immunization, mice were infected by aerosol with *M. tuberculosis* H37Rv. A culture suspension with an OD₆₀₀ of 0.850 was diluted ~100-fold and then used for aerosol infection. The concentration of the bacterial suspension was 4.73 \log_{10} CFU/mL, which resulted in a mean implantation of 2.11 (SD 0.09) \log_{10} CFU/lung. This implantation was approximately 1 \log_{10} CFU higher than was intended. By Day 0, the *M. tuberculosis* burden had stabilized at around

4.8 \log_{10} CFU/lung, with similar lung burdens observed in the untreated mice at Weeks 4, 8, and 12. Thus, despite the higher implantation, a stable *M. tuberculosis* infection was established in the lungs of these mice, with the stabilized lung CFU burden correspondingly nearly 1 \log_{10} CFU higher than observed in previous experiments 5 (1-3).

Assessment of bactericidal activity (Table 2). Compared to the *M. tuberculosis* CFU counts in the lungs of untreated mice, the R₁₀ (5/7) control regimen reduced the mean CFU count by approximately 1, 2 and 3 \log_{10} CFU/lung after 4, 8, and 12 weeks of 10 treatment, respectively. The P₁₅H₅₀ (1/7) control regimen resulted in reductions of about 2, 3, and 4.5 \log_{10} CFU after 4, 8, and 12 weeks of treatment, respectively. The relative magnitudes of the decline in lung CFU counts for both control regimens are as 15 expected based on previous studies (1,2). B₂₅ (5/7) resulted in a reduction of about 1.7, 4.0, and 4.9 \log_{10} CFU/lung after 4, 8, and 12 weeks of treatment, results which were also expected based on previous studies (1-2). Thus, the higher implantation and Day 15 CFU counts did not affect the relative activity of the drugs against this stabilized bacterial population in the mouse lungs.

For all B test regimens, there was increasing activity with increasing dose observed at 20 Weeks 4, 8, and 12. For mice that received one or two doses of B_{LA-160} (1/28), the decrease in lung CFU counts relative to untreated mice was equivalent to the decrease in mice that received the same total dose administered as a daily oral regimen, B₈ (5/7), for 4 or 8 weeks, respectively ($p > 0.05$ at both time points). One dose of B_{LA-160}, 25 delivering 160 mg/kg at Day 0, resulted in a decline of about 1.3 \log_{10} CFU/lung, and four weeks of B₈ (5/7) resulted in a decline of about 1.5 \log_{10} CFU/lung. After two doses of B_{LA-160} (1/28) or 8 weeks of B₈ (5/7), the CFU counts in the lungs decreased by an additional 1 \log_{10} in mice that received either of these regimens. After 12 weeks of treatment, the CFU counts in the lungs were lower in mice that had received one dose of B_{LA-160} than in the mice that received the same total dose of bedaquiline 30 (160 mg/kg) via daily dosing with B_{2.67} (5/7) ($p = 0.0002$), with the former regimen resulting in a decline of about 3 \log_{10} CFU/lung and the latter resulting in a decline of 1.7 \log_{10} CFU/lung, compared to the lung counts in the untreated control mice. In mice 35 that received a total bedaquiline dose of 320 mg/kg, either through two doses of B_{LA-160} or through daily dosing of B_{5.33} (5/7), the decline in lung CFU counts was the same at about 3 \log_{10} CFU/lung ($p > 0.05$). For mice that received a total bedaquiline dose of 480 mg/kg via three doses of B_{LA-160} (1/28), the lung CFU counts were higher than in

mice that received the equivalent total dose through daily dosing with B₈ (5/7), although the difference was not statistically significant.

After 12 weeks of treatment, nearly all test regimens had equivalent bactericidal activity as the R₁₀ (5/7) control regimen, with only the B_{2.67} (5/7) regimen being significantly less bactericidal than this control ($p < 0.0001$). The test regimen B₈ (5/7) demonstrated equivalent bactericidal activity to both the P₁₅H₅₀ (1/7) and B₂₅ (5/7) control regimens, while all other test regimens were significantly less bactericidal than either of these control regimens at Week 12. However, CFU data recorded at the Week 10 time point may not reflect the overall efficacy of long-acting bedaquiline regimens. In mice that received a single dose of B_{LA-160} on Day 0, bacterial killing was still observed 12 weeks after administration. Thus, it is conceivable that the bacterial burden in the lungs of mice that received 2 and 3 doses of B_{LA-160} would still further decrease for at least 12 weeks after administration of the last dose (if not longer). Also of interest 15 is that the single dose of B_{LA-160} seemed to exert greater bactericidal activity from weeks 1 to 4 and from weeks 9 to 12, compared to weeks 5 to 8 post-administration, suggesting the possibility of biphasic B release kinetics from the long-acting vehicle.

CONCLUSIONS

- 20 ○ Despite a higher bacterial implantation than anticipated, a stable *M. tuberculosis* infection was established in BALB/c mice that was suitable for evaluation of LTBI treatment regimens.
- 25 ○ After 12 weeks of treatment, once-monthly dosing with B_{LA-160} demonstrated superior or equivalent bactericidal activity compared to daily dosing for total bedaquiline doses of 160 or 320 and 480 mg/kg, respectively.
- 30 ○ The bactericidal activity observed from a single dose of B_{LA-160} was evident for at least 12 weeks after administration, and likely CFU counts would continue to decrease in the lungs of mice that received 2 and 3 doses. Taken together with the higher-than-expected baseline bacterial burden in this experiment, these findings suggest that cure after 2 or 3 injections may be possible. Thus, it will be critical to evaluate the sterilizing activity of these B_{LA} regimens over longer time periods to truly understand their potential for use in LTBI treatment.

REFERENCES

- 1) Zhang, T., Li, S., Williams, K., Andries, K., Nuermberger, E. 2011. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. *Am. J Respir. Crit. Care Med.* 184:732-737.
- 5 2) Lanoix, J.P., Betoudji, F., Nuermberger, E. 2014. Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of multidrug-resistant tuberculosis cases. *Antimicrob. Agents Chemother.* 58:2316-2321.
- 3) Zhang, T., M. Zhang, I. M. Rosenthal, J. H. Grosset, and E. L. Nuermberger. 2009. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis 10 infection. *Am.J Respir.Crit Care Med.* 180:1151-1157.

Editorial Note

2018298855

New claims are non-sequential,
there is no claim 14.

Claims 1-13 and 15-22

Claims

1. A pharmaceutical composition for administration by intramuscular or subcutaneous injection, comprising a therapeutically effective amount of bedaquiline, or a pharmaceutically acceptable salt thereof, in the form of a suspension of micro- or nanoparticles comprising:
 - (a) bedaquiline, or a pharmaceutically acceptable salt thereof, in micro- or nanoparticle form, and a surface modifier; and
 - (b) a pharmaceutically acceptable aqueous carrier.
2. A composition according to claim 1, wherein the surface modifier is selected from the group of poloxamers, α -tocopheryl polyethylene glycol succinates, polyoxyethylene sorbitan fatty acid esters, and salts of negatively charged phospholipids.
3. A composition according to claim 1 or 2, wherein bedaquiline is in its non-salt or free form or in the form of a fumarate salt.
4. A composition according to any one of claims 1 to 4, wherein the surface modifier is selected from PluronicTM F108, Vitamin E TGPS, TweenTM 80, and LipoïdTM EPG
5. A composition according to any one of claims 1 to 4, wherein the average effective particle size of the bedaquiline, or a pharmaceutically acceptable salt thereof, micro- or nanoparticles is below about 50 μ m, in particular below about 200 nm.
6. A composition according to any one of claims 1 to 4, wherein the average effective particle size of the bedaquiline, or a pharmaceutically acceptable salt thereof, micro- or nanoparticles is about 130 nm.
7. A composition according to claim 1 or 2, comprising by weight based on the total volume of the composition:
 - (a) from 10% to 70% (w/v), or from 20% to 60% (w/v), or from 20% to 50% (w/v), or from 20% to 40% (w/v) of bedaquiline (or pharmaceutically acceptable salt thereof; but where the w/v is calculated on the basis of its non-salt form);
 - (b) from 0.5% to 20 %, or from 2% to 15% or 20% (w/v), or from 5% to 15% (w/v) of a wetting agent;

- (c) from 0% to 10%, or from 0% to 5%, or from 0% to 2%, or from 0% to 1% of one or more buffering agents;
 - (d) from 0% to 20 %, or from 2% to 15% or 20% (w/v), or from 5% to 15% (w/v) of a isotonizing agent
 - (e) from 0% to 2% (w/v) preservatives; and
 - (f) water for injection q.s. ad 100%.
8. The pharmaceutical composition as defined in any one of claims 1 to 7, for use in medicine.
9. The use of a pharmaceutical composition as defined in any one of claims 1 to 7, in the manufacture of a medicament for the treatment of a pathogenic mycobacterial infection.
10. The use of claim 9 wherein the medicament is for the long-term treatment of *Mycobacterium tuberculosis* (such as the latent/dormant form) or *Mycobacterium leprae*.
11. The use according to claim 9 wherein the medicament is for administration by intramuscular or subcutaneous injection; wherein the composition is administered intermittently at a time interval of one week to two years.
12. The use according to claim 9 wherein the pharmaceutical composition is administered at an interval of at least one month to one year.
13. The use according to claim 9, wherein the pharmaceutical composition is administered at a time interval that is in the range of one week to one month, or in the range of one month to three months, or in the range of three months to six months, or in the range of six months to twelve months, or in the range of 12 months to 24 months.
15. The use according to claim 9, wherein the pharmaceutical composition is administered once every two weeks, or once every month, or once every three months.
16. A method of treating a pathogenic mycobacterial infection, comprising administering the pharmaceutical composition as defined in any one of claims 1 to 7, to a subject in need thereof.

17. The method of claim 16 wherein the medicament is for the long-term treatment of *Mycobacterium tuberculosis* (such as the latent/dormant form) or *Mycobacterium leprae*.
18. The method according to claim 16 wherein the medicament is administered by intramuscular or subcutaneous injection; wherein the composition is administered intermittently at a time interval of one week to two years.
19. The method according to claim 16 wherein the pharmaceutical composition is administered at an interval of at least one month to one year.
20. The method according to claim 16, wherein the pharmaceutical composition is administered at a time interval that is in the range of one week to one month, or in the range of one month to three months, or in the range of three months to six months, or in the range of six months to twelve months, or in the range of 12 months to 24 months.
21. The method according to claim 16, wherein the pharmaceutical composition is administered once every two weeks, or once every month, or once every three months.
22. A process for preparing a pharmaceutical composition as defined in any one of claims 1 to 7, comprising
 - (a) obtaining bedaquiline, or a pharmaceutically acceptable salt thereof, in micronized form;
 - (b) adding the micronized bedaquiline, or a pharmaceutically acceptable salt thereof, to a liquid medium to form a premix/predispersion; and
 - (c) subjecting the premix to mechanical means in the presence of a grinding medium to reduce the average effective particle size.




Figure 1




Figure 2




Figure 3

4/7




Figure 4

5/7




Figure 5




Figure 6




Figure 7